Back to GetFilings.com
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-K
(Mark One)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the fiscal year ended December 31, 2002
-----------------
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from to
---------- ---------
Commission file number 0-22245
NEXMED, INC
(Exact Name of Registrant as Specified in Its Charter)
NEVADA 87-0449967
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)
350 CORPORATE BOULEVARD, ROBBINSVILLE, NJ 08691
(Address of Principal Executive Offices)
(609) 208-9688
(Registrant's telephone number)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class Name of Exchange on Which Registered
------------------- ------------------------------------
COMMON STOCK, PAR VALUE $.001 THE NASDAQ NATIONAL MARKET
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [ ]
Indicate by check mark whether the registrant is an accelerated filer
(as defined in Exchange Act Rule 12b-2) Yes [ ] No [X]
As of June 30, 2002, the aggregate market value of the common stock
held by non-affiliates was approximately $65,828,310.
As of March 24, 2003 28,678,933 shares of the common stock, par value
$.001, of the registrant were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of our Proxy Statement to be delivered to our stockholders in
connection with the Annual Meeting of Stockholders to be held on June 16, 2003
(the "2003 Proxy Statement") are incorporated by reference into Part III of this
Report.
NEXMED, INC.
INDEX TO ANNUAL REPORT ON FORM 10-K FILED WITH
THE SECURITIES AND EXCHANGE COMMISSION
YEAR ENDED DECEMBER 31, 2002
ITEMS IN FORM 10-K
Page
PART I.
Item 1. BUSINESS......................................................................................... 1
Item 2. PROPERTIES....................................................................................... 9
Item 3. LEGAL PROCEEDINGS................................................................................ 9
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.............................................. 9
PART II.
Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER
MATTERS.......................................................................................... 9
Item 6. SELECTED FINANCIAL DATA.......................................................................... 10
Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS............................................................................ 10
Item 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK....................................... 17
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA...................................................... 17
Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE........................................................................ 38
PART III.
Item 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT............................................... 38
Item 11. EXECUTIVE COMPENSATION........................................................................... 38
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS.............................................................................. 38
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS................................................... 38
Item 14. CONTROLS AND PROCEDURES ......................................................................... 38
PART IV.
Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K.................................. 38
PART I.
ITEM 1. BUSINESS.
Some of the statements contained in this Report discuss future
expectations, contain projections of results of operations or financial
condition or state other "forward-looking" information. Those statements include
statements regarding the intent, belief or current expectations of the Company
and its management team. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance and involve
risks and uncertainties, and that actual results may differ materially from
those projected in the forward-looking statements. These risks and uncertainties
include but are not limited to, those risks and uncertainties set forth under
the heading "Factors That Could Affect Our Future Results" of Part I of this
Report. In light of the significant risks and uncertainties inherent in the
forward-looking statements included in this Report, the inclusion of such
statements should not be regarded as a representation by us or any other person
that our objectives and plans will be achieved.
GENERAL
NexMed, Inc., (the "Company," which may be referred to as "we," "us," or
"our") is a pharmaceutical and medical technology company. We develop
therapeutic products based on proprietary delivery systems for
commercialization. We are currently focusing our efforts on new and patented
topical pharmaceutical products based on a penetration enhancement drug delivery
technology known as NexACT(R), which may enable an active drug to be better
absorbed through the skin.
PRODUCTS & TECHNOLOGIES
We are currently focusing our efforts on new and patented topical
pharmaceutical products based on a penetration enhancement drug delivery
technology known as NexACT(R), which may enable an active drug to be better
absorbed through the skin. The NexACT(R) transdermal drug delivery technology is
designed to enhance the absorption of an active drug through the skin,
overcoming the skin's natural barrier properties and enabling high
concentrations of the active drug to rapidly penetrate the desired site of the
skin or extremity. Successful application of the NexACT(R) technology would
improve therapeutic outcomes and reduce gastrointestinal or other systemic side
effects that often accompany oral medications.
We intend to continue our efforts developing topical treatments including
cream, gel, patch and tape, based on the application of NexACT(R) technology to
drugs: (1) previously approved by the FDA, (2) with proven efficacy and safety
profiles, (3) with patents expiring or expired and (4) with proven market track
records and potential.
We are focusing our application of the NexACT(R) technology to
Alprox-TD(R) cream for the treatment of male erectile dysfunction ("ED"). We are
also developing Femprox(R) cream for female sexual arousal disorder ("FSAD"). We
have explored the application of the NexACT(R) technology to other drug
compounds and delivery systems, and are in the early stages of developing new
topical treatments for nail fungus, premature ejaculation, urinary incontinence,
wound healing, and the prevention of nausea and vomiting associated with
post-operative surgical procedures and cancer chemotherapy.
Alprox-TD(R) is an alprostadil-based cream treatment intended for
patients with mild, moderate or severe ED. Our clinical studies have
demonstrated that NexACT(R) enhancers promote the rapid absorption of
alprostadil and improve clinical responses. In December 2002, we completed our
two pivotal Phase 3 studies for Alprox-TD(R), which tested over 1,300 patients
at 82 sites throughout the U.S. The two pivotal studies were randomized,
double-blind, placebo-controlled, and designed to confirm the efficacy and
safety of Alprox-TD(R) in patients with various degrees of ED. We are currently
reviewing and analyzing the data from the two pivotal studies and pending
adequate financing, anticipate announcing the preliminary results during second
quarter of 2003.
In March 2002, we initiated a Phase 3 open-label study for Alprox-TD(R).
The purpose of the new study was to confirm the safety of Alprox-TD(R) on a
longer term basis and included new patients as well as those who completed
testing in one of the two pivotal Phase 3 studies and elected to continue using
Alprox-TD(R) for an additional period. In
1
November 2002, we halted the open-label study of Alprox-TD(R) due to the FDA
concerns about results of our 26-week transgenic mice study. In January 2003, we
met with the FDA and successfully addressed their issues regarding the results
of the transgenic mice study and in February 2003, we were cleared by the FDA to
continue with the open-label study of Alprox-TD(R). However, it remains to be
determined by the FDA if any data from the halted study can be used for our
filing of the New Drug Application ("NDA") for Alprox-TD(R). Assuming that we do
not include the data from the halted study and that we have financing to
initiate a new open-label study by July 2003, we anticipate that we will file
the NDA during the first half of 2004. Completion of the open-label study is not
a prerequisite for our NDA submission; however, it is possible that we may not
have successful clinical results or receive FDA approval on a timely basis, if
at all.
In April 2002, Alprox-TD(R) was launched in Hong Kong under the Befar(R)
trademark. The product, which has been selling in China since October 2001, is
manufactured and marketed by a local affiliate of Vergemont International
Limited, our Asian licensee. We receive from our Asian licensee royalty payments
and payments for manufacturing supplies in connection with the distribution of
Befar(R) in China and will receive such payments in other Asian markets once
Befar(R) is approved for marketing in such other markets. Befar(R), along with
the currently approved oral erectile dysfunction product, are currently
classified in China as controlled substances, and their distribution is limited
to prescription by certain urologists and dispensing through hospitals. In
addition, China has a limited number of patients who can afford erectile
dysfunction treatments. In December 2002, our Asian licensee entered into a
licensing agreement with CJ Corporation, one of the five largest pharmaceutical
companies in South Korea. Pursuant to the terms of the agreement, CJ Corporation
will develop, file for regulatory approval, market and distribute Befar(R) in
South Korea. Our Asian licensee also has an NDA pending with the Health Science
Authority for approval to market the product in Singapore.
Femprox(R) is an alprostadil-based cream product intended for the
treatment of FSAD. We have completed the testing of 98 patients for a Phase 2
clinical study with Femprox(R). This multi-center at home use study is
randomized, double-blind, placebo-controlled, and designed to investigate the
efficacy and safety of the Femprox(R) cream in pre-menopausal women diagnosed
with FSAD. We intend to continue with the clinical development of Femprox(R)
pending the availability of financing and/or a partnering agreement.
We are working with various pharmaceutical companies in order to explore
the introduction of NexACT(R) into their existing drugs as a means of developing
new patient-friendly topical products and extending patent lifespans. In August
2002, we entered into a research and development agreement with a major Japanese
pharmaceutical company. Pursuant to the terms of this agreement, we will develop
a new tape/patch treatment for urinary dysfunction which incorporates the
Japanese partner's proprietary drug compound with the NexACT(R) technology. We
received an upfront payment of 10 million Japanese Yen (approximately $90,000)
with future periodic payments of up to 40 million Japanese Yen (approximately
$360,000) to be made based on the achievement of certain development milestones.
We will also retain the right to manufacture and commercialize the new product
worldwide except in Japan. We anticipate that we will enter into additional R&D
agreements during 2003 but we cannot assure you that we will be able to conclude
any arrangement on a timely basis, if at all, or on terms acceptable to us.
Another product, which we have developed, is the Viratrol(R) device, a
therapeutic medical device for the treatment of herpes simplex diseases without
the use of drugs. The Viratrol(R) device is hand-held, non-invasive, and
designed to treat herpes simplex lesions. The device topically delivers a minute
electrical current to an infected site and may block lesions from forming and/or
shorten healing time once lesions develop. The development program for the
Viratrol(R) device is on hold pending our entering into a partnering agreement.
2
FACTORS THAT COULD AFFECT OUR FUTURE RESULTS
RISKS RELATED TO THE COMPANY
WE HAVE AN URGENT NEED FOR ADDITIONAL FINANCING.
We are currently continuing with the development of Alprox-TD(R) at a
significantly reduced level and have put on hold the development of Femprox(R)
and other pipeline products, pending the availability of financing. Our cash
position as of March 24, 2003 is approximately $400,000. We will need an
additional cash infusion of approximately $3 million prior to being able to
resume research and development of our pipeline products including Alprox-TD(R)
at a consistent level. We have been actively seeking financing from the sale of
equity or issuance of debt from private and public sources as well as from
collaborative licensing and/or marketing arrangements with third parties, and
since December 31, 2002, we have raised approximately $2 million net through the
exercise of warrants to purchase shares of our common stock and the issuance by
the Company of notes, common stock and warrants to purchase shares of common
stock (see Note 15 to the Consolidated Financial Statements). Our anticipated
cash requirements for Alprox-TD(R) through the NDA filing in the first half of
2004 will be approximately $15 million. Completion of the open-label study is
not a prerequisite for our NDA submission. We may not be able to arrange for the
financing of that amount, and if we are not successful in entering into a
licensing agreement for Alprox-TD(R), we may be required to discontinue the
development of Alprox-TD(R).
OUR STOCK MAY BE DELISTED FROM NASDAQ, WHICH MAY MAKE IT MORE DIFFICULT FOR YOU
TO SELL YOUR SHARES.
Currently, our common stock trades on the Nasdaq National Market. During
the past year, our stock, at times, traded below $1.00 per share. NASD
Marketplace Rule 4450(b) provides for continued listing rules and a company who
lists on the Nasdaq National Market must meet all of the requirements under at
least one continued listing standard to maintain its listing. If a company
failures to meet the continued listing requirements, it faces possible delisting
from the Nasdaq National Market.
On December 31, 2002, we received notification from the NASD that our
common stock had closed below the minimum $1.00 per share required for continued
inclusion on the Nasdaq for a period of more than thirty consecutive trading
days. In its notification, the NASD informed us that we have 90 calendar days,
or until March 31, 2003, to comply with NASD Marketplace Rule 4450(a)(5). In
order to comply with this rule, the bid price of our common stock must close at
$1.00 per share or more for a minimum of ten consecutive trading days at any
time before March 31, 2003. As of February 11, 2003, the closing bid price of
our common stock had remained equal to $1.00 per share or greater for more than
ten consecutive trading days. On January 29, 2003, we received affirmative
notification from Nasdaq that we had regained compliance with Rule 4450(a)(5),
and that the matter was therefore closed.
As of December 31, 2002, our Stockholders' Equity was $3.6 million, which
is below the $10 million as required by Rule 4450(a)(1). We anticipate that we
will receive a notification from the NASD regarding this matter and be given a
period of time to remedy the situation or face possible delisting from Nasdaq
National Market.
If we were to be delisted from the Nasdaq National Market, our common
stock would be listed on the Nasdaq SmallCap Market, assuming we meet those
listing requirements. If we fail to meet the Nasdaq SmallCap listing
requirements, our stock would be considered a penny stock under regulations of
the Securities and Exchange Commission and would therefore be subject to rules
that impose additional sales practice requirements on broker-dealers who sell
our securities. The additional burdens imposed upon broker-dealers by these
requirements could discourage broker-dealers from effecting transactions in our
common stock, which could severely limit the market liquidity of the common
stock and your ability to sell our securities in the secondary market.
WE CONTINUE TO INCUR OPERATING LOSSES.
Our current business operations began in 1994 and we have a limited
operating history. We may encounter delays, uncertainties and complications
typically encountered by development stage businesses. We have generated minimal
revenues from the limited sales of Befar(R) in Asia and our existing research
and development agreement with the Japanese partner, and have not marketed or
generated revenues in the U.S. from our products under development. We are not
profitable and have incurred an accumulated deficit of $67,987,969 since our
inception. Our current ability to generate revenues and to achieve profitability
and positive cash flow will depend on the successful commercialization of our
products currently under development. Thus far, we have generated only minimal
revenues from the limited sales of Befar(R) in Asia and from the research and
development agreement with our Japanese partner, and have not marketed or
generated revenues in the U.S. from our products under development. However,
even if we eventually generate
3
revenues from sales of our products currently under development, we expect to
incur significant operating losses over the next several years.
OUR INDEPENDENT ACCOUNTANTS HAVE DOUBT AS TO OUR ABILITY TO CONTINUE AS A GOING
CONCERN FOR A REASONABLE PERIOD OF TIME.
As a result of our losses to date, working capital deficiency and
accumulated deficit, our independent accountants have concluded that there is
substantial doubt as to our ability to continue as a going concern for a
reasonable period of time, and have modified their report in the form of an
explanatory paragraph describing the events that have given rise to this
uncertainty. Our continuation is based on our ability to generate or obtain
sufficient cash to meet our obligations on a timely basis and ultimately to
attain profitable operations. Our independent auditors' going concern
qualification may make it more difficult for us to obtain additional funding to
meet our obligations. We anticipate that we will continue to incur significant
losses until successful commercialization of one or more of our products, and we
may never operate profitably in the future.
WE WILL NEED SIGNIFICANT FUNDING TO COMPLETE OUR RESEARCH AND DEVELOPMENT
EFFORTS.
Our research and development expenses for the years ended December 31,
2002, 2001, and 2000 were $21,615,787, $12,456,384, and $6,892,283,
respectively. Since January 1, 1994, when we repositioned ourselves as a medical
and pharmaceutical technology company, we have spent $50,695,348 on research and
development. We anticipate that our expenses for research and development will
not increase in 2003. Given our current lack of cash reserves, we will not be
able to advance the development of our products unless we raise additional cash
reserves through financing from the sale of our securities and/or through
partnering agreements. If we are successful in entering partnering agreements
for our products under development, we will receive milestone payments, which
will offset some of our research and development expenses.
As indicated above, our anticipated cash requirements for Alprox-TD(R)
through the NDA filing in the first half of 2004, will be approximately $15
million. Completion of the open label study is not a prerequisite for our NDA
filing. We may not be able to arrange for the financing of that amount, and if
we are not successful in entering enter into a licensing agreement for
Alprox-TD(R), we may be required to discontinue the development of Alprox-TD(R).
We will also need significant funding to pursue our product development
plans. In general, our products under development will require significant
time-consuming and costly research and development, clinical testing, regulatory
approval and significant additional investment prior to their commercialization.
The research and development activities we conduct may not be successful; our
products under development may not prove to be safe and effective; our clinical
development work may not be completed; and the anticipated products may not be
commercially viable or successfully marketed. Commercial sales of our products
cannot begin until we receive final FDA approval. The earliest time for such
final approval of the first product which may be approved, Alprox-TD(R), is
sometime in early 2005. We intend to focus our current development efforts on
the Alprox-TD(R) cream treatment, which is in the late clinical development
stage.
PRE-CLINICAL AND CLINICAL TRIALS ARE INHERENTLY UNPREDICTABLE. IF WE DO NOT
SUCCESSFULLY CONDUCT THESE TRIALS, WE MAY BE UNABLE TO MARKET OUR PRODUCTS.
Through pre-clinical studies and clinical trials, we must demonstrate that
our products are safe and effective for their indicated uses. Results from
pre-clinical studies and early clinical trials may not allow us to predict
results in later-stage testing. Our future clinical trials may not demonstrate
the safety and effectiveness of any of our products or may not result in
regulatory approval to market our products. The failure of the FDA to approve
our products for commercial sales will have a material adverse effect on our
prospects.
PATENTS AND INTELLECTUAL PROPERTY RIGHTS ARE IMPORTANT TO US BUT COULD BE
CHALLENGED.
Proprietary protection for our pharmaceutical products is of material
importance to our business in the U.S. and most other countries. We have and
will continue to seek proprietary protection for our products to attempt to
prevent others from commercializing equivalent products in substantially less
time and at substantially lower expense. Our
4
success may depend on our ability to (1) obtain effective patent protection
within the U.S. and internationally for our proprietary technologies and
products, (2) defend patents we own, (3) preserve our trade secrets, and (4)
operate without infringing upon the proprietary rights of others.
We have nine U.S. patents either acquired or received out of a series of
patent applications that we have filed in connection with our NexACT(R)
technology and our NexACT-based products under development, such as Alprox-TD(R)
Femprox(R), and our non-steroidal anti-inflammatory cream. We have three U.S.
patents issued on the Viratrol(R) device and one patent application pending with
respect to the technology, inventions and improvements that are significant to
the Viratrol(R) device. To further strengthen our global patent position on our
proprietary products under development, and to expand the patent protection to
other markets, we have filed under the Patent Cooperation Treaty, corresponding
international applications for our issued U.S. patents and pending U.S. patent
applications.
The following table identifies our nine U.S. patents issued for NexACT(R)
technology and/or our NexACT-based products under development, and the year of
expiration for each patent:
Patent Name Expiration Date
- ----------- ---------------
Topical Compositions Containing Prostaglandin E1 2019
Prostaglandin Composition and Methods of Treatment of Male ED 2020
Compositions and Methods for Amelioration of Human Female Sexual Dysfunction 2017
Topical Compositions for PGE1 Delivery 2017
Topical Compositions for Non-Steroidal Anti-Inflammatory Drug Delivery 2017
Biodegradable Absorption Enhancers 2012
Biodegradable Absorption Enhancers 2010
Medicament Dispenser 2019
Crystalline Salts of dodecyl 2-(N, N-Dimethylamino) 2019
While we have obtained patents and have several patent applications
pending, the extent of effective patent protection in the U.S. and other
countries is highly uncertain and involves complex legal and factual questions.
No consistent policy addresses the breadth of claims allowed in or the degree of
protection afforded under patents of medical and pharmaceutical companies.
Patents we currently own or may obtain might not be sufficiently broad to
protect us against competitors with similar technology. Any of our patents could
be invalidated or circumvented.
There have been patents issued to others such as Vivus, Inc. and
MacroChem Corporation on the use of alprostadil for the treatment of male or
female sexual dysfunction. While we believe that our patents will prevail in any
potential litigation, the holders of these competing patents could determine to
commence a lawsuit against us and even prevail in any such lawsuit. Litigation
could result in substantial cost to and diversion of effort by us, which may
harm our business. In addition, our efforts to protect or defend our proprietary
rights may not be successful or, even if successful, may result in substantial
cost to us.
WE DEPEND UPON THIRD PARTY MANUFACTURERS FOR OUR CHEMICAL MANUFACTURING
SUPPLIES.
In 2002, we completed the construction of a 31,500 square foot industrial
facility, located in East Windsor, New Jersey, which we are in the process of
developing and validating as a manufacturing facility designed to meet the Good
Manufacturing Practice (GMP) standards required by the FDA. We anticipate that
our manufacturing facility will have the capacity to meet our anticipated needs
for full-scale commercial production. Initially, we are utilizing the facility
to manufacture Alprox-TD(R) and other NexACT(R)-based products under development
for continuing clinical testing purposes.
In this regard, we depend on third party chemical manufacturers for
alprostadil, the active drugs in Alprox-TD(R) and in other NexACT-based products
under development, and for the supply of our NexACT(R) enhancers that are
essential in the formulation and production of our topical products, on a timely
basis and at satisfactory quality levels. If our validated third party chemical
manufacturers fail to produce quality products on time and in sufficient
qualities, our results would suffer, as we would encounter costs and delays in
revalidating new third party suppliers.
5
WE FACE SEVERE COMPETITION.
We are engaged in a highly competitive industry. We expect increased
competition from numerous existing companies, including large international
enterprises, and others entering the industry. Most of these companies have
greater research and development, manufacturing, marketing, financial,
technological, personnel and managerial resources. Acquisitions of competing
companies by large pharmaceutical or healthcare companies could further enhance
such competitors' financial, marketing and other resources. Competitors may
complete clinical trials, obtain regulatory approvals and commence commercial
sales of their products before we could enjoy a significant competitive
advantage. Products developed by our competitors may be more effective than our
products.
Certain treatments for ED, such as needle injection therapy, vacuum
constriction devices, penile implants, transurethral absorption and oral
medications, currently exist, have been approved for sale in certain markets and
are being improved. Currently known products for the treatment of ED developed
or under development by our competitors include the following: (1) Caverject(R),
Pharmacia & Upjohn Company's needle injection therapy; (2) Viagra(R), Pfizer,
Inc.'s oral product to treat ED; and (3) Muse(R), Vivus, Inc.'s device for
intra-urethral delivery of a suppository containing alprostadil. In addition,
the following products are currently under development: (1) Topiglan(R), a
topical treatment containing alprostadil based on a proprietary drug delivery
system under development by MacroChem Corporation; (2) Cialis(R), an oral
formulation to be marketed in the U.S. through a joint venture between ICOS and
Eli Lilly & Co; (3) Uprima(R), an oral medication to be marketed in the U.S. by
TAP Pharmaceuticals, a joint venture between Takeda Pharmaceuticals Japan and
Abbott Laboratories; and (4) Levitra(R), an oral medication to be marketed
through a collaborative effort of Bayer AG and GlaxoSmithKline, Inc.
WE WILL NEED TO PARTNER TO OBTAIN EFFECTIVE SALES, MARKETING AND DISTRIBUTION.
We currently have no sales force or marketing organization and will need,
but may be unable, to attract and retain qualified or experienced marketing and
sales personnel. We will need to secure a marketing partner who is able to
devote substantial marketing efforts to achieve market acceptance for our
proprietary products under development. The marketing partner will need to spend
significant funds to inform potential customers, including third-party
distributors, of the distinctive characteristics and benefits of our products.
Our operating results and long term success will depend, among other things, on
our ability to establish (1) successful arrangements with domestic and
international distributors and marketing partners and (2) an effective internal
marketing organization. We have engaged in discussions with several large
pharmaceutical companies regarding a strategic partnership for the Alprox-TD(R)
cream but we may not be able to conclude an arrangement on a timely basis, if at
all, or on terms acceptable to us.
In Asia, our subsidiary, NexMed International Limited, and our Asian
licensee, Vergemont International Limited, entered into a license agreement in
1999 pursuant to which (1) Vergemont International Limited has an exclusive
right to manufacture and to market in Asian Pacific countries, our Alprox-TD(R),
Femprox(R) and three other of our proprietary products under development, and
(2) we will receive a royalty on sales and supply, on a cost plus basis, the
NexACT(R) enhancers that are essential in the formulation and production of our
proprietary topical products. In 2002, we recorded modest payments from our
Asian licensee for royalty on sales of Befar(R) in China and Hong Kong and for
manufacturing supplies purchased from us.
WE MAY BE SUBJECT TO POTENTIAL PRODUCT LIABILITY CLAIMS, CREATING RISK AND
EXPENSE.
We are exposed to potential product liability risks inherent in the
development, testing, manufacturing, marketing and sale of human therapeutic
products. Product liability insurance for the pharmaceutical industry is
extremely expensive, difficult to obtain and may not be available on acceptable
terms, if at all. We currently have liability insurance to cover claims related
to our products that may arise from clinical trials, with coverage of $1 million
for any one claim and coverage of $3 million in total, but we do not maintain
product liability insurance and we may need to acquire such insurance coverage
prior to the commercial introduction of our products. If we obtain such
coverage, we have no guarantee that the coverage limits of such insurance
policies will be adequate. A successful claim against us if we are uninsured, or
which is in excess of our insurance coverage, if any, could have a material
adverse effect upon us and on our financial condition.
6
INDUSTRY RISKS
WE ARE VULNERABLE TO VOLATILE MARKET CONDITIONS.
The market prices for securities of biopharmaceutical and biotechnology
companies, including ours, have been highly volatile. The market has from time
to time experienced significant price and volume fluctuations that are unrelated
to the operating performance of particular companies. In addition, future
announcements, such as the results of testing and clinical trials, the status of
our relationships with third-party collaborators, technological innovations or
new therapeutic products, governmental regulation, developments in patent or
other proprietary rights, litigation or public concern as to the safety of
products developed by us or others and general market conditions, concerning us,
our competitors or other biopharmaceutical companies, may have a significant
effect on the market price of our common stock.
WE ARE SUBJECT TO NUMEROUS AND COMPLEX GOVERNMENT REGULATIONS.
Governmental authorities in the U.S. and other countries heavily regulate
the testing, manufacture, labeling, distribution, advertising and marketing of
our proposed products. None of our proprietary products under development has
been approved for marketing in the U.S. Before we market any products we
develop, we must obtain FDA and comparable foreign agency approval through an
extensive clinical study and approval process.
The studies involved in the approval process are conducted in three
phases. In Phase 1 studies, researchers assess safety or the most common acute
adverse effects of a drug and examine the size of doses that patients can take
safely without a high incidence of side effects. Generally, 20 to 100 healthy
volunteers or patients are studied in the Phase 1 study for a period of several
months. In Phase 2 studies, researchers determine the drug's efficacy with
short-term safety by administering the drug to subjects who have the condition
the drug is intended to treat, assess whether the drug favorably affects the
condition, and begin to identify the correct dosage level. Up to several hundred
subjects may be studied in the Phase 2 study for approximately 6 to 12 months,
depending on the type of product tested. In Phase 3 studies, researchers further
assess efficacy and safety of the drug. Several hundred to thousands of patients
may be studied during the Phase 3 studies for a period of from 12 months to
several years. Upon completion of Phase 3 studies, a NDA is submitted to the FDA
or foreign governmental regulatory authority for review and approval.
Because we intend to sell and market our products outside the U.S., we
will be subject to foreign regulatory requirements governing the conduct of
clinical trials, product licensing, pricing and reimbursements. These
requirements vary widely from country to country. Our failure to meet each
foreign country's requirements could delay the introduction of our proposed
products in the respective foreign country and limit our revenues from sales of
our proposed products in foreign markets.
Successful commercialization of our products may depend on the
availability of reimbursement to the consumer from third-party healthcare
payers, such as government and private insurance plans. Even if we succeed in
bringing one or more products to market, reimbursement to consumers may not be
available or sufficient to allow us to realize an appropriate return on our
investment in product development or to sell our products on a competitive
basis. In addition, in certain foreign markets, pricing or profitability of
prescription pharmaceuticals is subject to governmental controls. In the U.S.,
federal and state agencies have proposed similar governmental control and the
U.S. Congress has recently considered legislative and regulatory reforms that
may affect companies engaged in the healthcare industry. Pricing constraints on
our products in foreign markets and possibly in the U.S. could adversely affect
our business and limit our revenues.
WE ARE SUBJECT TO ENVIRONMENTAL LAW COMPLIANCE.
Most of our manufacturing and certain research operations are or will be
affected by federal, state and local environmental laws. We have made, and
intend to continue to make, necessary expenditures for compliance with
applicable laws. While we cannot predict with certainty the future operating
costs for environmental compliance, we do not believe they will have a material
effect on our capital expenditures, earnings or competitive position.
7
SEGMENT AND GEOGRAPHIC AREA INFORMATION
You can find information about our business segment and geographic areas
of business in Note 14 of the Notes to Consolidated Financial Statements.
EMPLOYEES
As of March 17, 2003, we had 44 full time employees, 8 of whom have Ph.D
and/or M.D. degrees, 4 of whom are executive management and 30 of whom are
engaged in research and development activities. We also rely on a number of
consultants. None of our employees is represented by a collective bargaining
agreement. We believe that our relationship with our employees is good.
EXECUTIVE OFFICERS
The Executive Officers of the Company are set forth below.
Name Age* Title
---- ---- -----
Y. Joseph Mo, Ph.D. 55 Chairman of the Board of Directors, President and Chief Executive Officer
James L. Yeager, Ph.D. 56 Director, Senior Vice President, Scientific Affairs
Vivian H. Liu 41 Vice President, Acting Chief Financial Officer and Secretary
Kenneth F. Anderson 56 Vice President, Commercial Development
* As of February 28, 2003.
Y. Joseph Mo, Ph.D., is, and has been since 1995, our Chief Executive
Officer and President and Chairman and member of our board of directors. Prior
to joining us in 1995, Dr. Mo was President of Sunbofa Group, Inc., a
privately-held investment consulting company. From 1991 to 1994, he was
President of the Chemical Division, and from 1988 to 1994, the Vice President of
Manufacturing and Medicinal Chemistry, of Greenwich Pharmaceuticals, Inc. Prior
to that, he served in various executive positions with several major
pharmaceutical companies, including Johnson & Johnson, Rorer Pharmaceuticals,
and predecessors of Smithkline Beecham. Dr. Mo received his Ph.D. in Industrial
and Physical Pharmacy from Purdue University in 1977.
James L. Yeager, Ph.D., is, and has been since December 1998, a member
of the Board of Directors and, since January 2002, Senior Vice President for
Scientific Affairs. From June 1996 through December 2001, Dr. Yeager served as
the Company's Vice President of Research and Development and Business
Development. Before joining the Company, Dr. Yeager was Vice President of
Research and Development at Pharmedic Company. From 1979 to 1992, Dr. Yeager
held various positions with Abbott Laboratories and Schiaparelli-Searle. Dr.
Yeager received his Ph.D. in Industrial and Physical Pharmacy from Purdue
University in 1978.
Vivian H. Liu is, and has been, our Vice President of Corporate Affairs
and Secretary since September 1995 and our Acting Chief Financial Officer since
August 1999. In 1994, while we were in a transition period, Ms. Liu served as
our Chief Executive Officer. From September 1995 to September 1997, Ms. Liu was
our Treasurer. From 1985 to 1994, she was a business and investment adviser to
the government of Quebec and numerous Canadian companies with respect to product
distribution, technology transfer and investment issues. Ms. Liu received her
MPA in International Finance from the University of Southern California and her
BA from the University of California, Berkeley.
Kenneth F. Anderson is, and has been, our Vice President of Commercial
Development since November 2000. Mr. Anderson has extensive experience in the
pharmaceutical industry. From 1997 to September 2000, Mr. Anderson was Senior
Vice President, Director of Strategy and Business Development for Harrison
Wilson & Associates, a consulting and marketing firm specializing in healthcare
products and services. From 1980 to 1997, Mr. Anderson was at Bristol-Myers
Squibb where he served in various management positions, including Senior Manager
for Marketing and Director for Worldwide Business Development. From 1969 to
1979, Mr. Anderson was with Parke-Davis, a division of Warner Lambert. Mr.
Anderson received his BA from Boston University.
8
ITEM 2. PROPERTIES.
We currently have our principal executive offices and laboratories in
Robbinsville, NJ. We lease approximately 24,000 square feet of space for $25,000
per month, pursuant to a lease, which expires in 2004. We also lease
approximately 5,000 square feet of laboratory space in Monmouth Junction, NJ for
$12,035 per month pursuant to a lease, which expires in 2004.
We own our 31,500 square foot manufacturing facility in East Windsor, New
Jersey. We purchased the facility for $2.2 million and have invested
approximately $5.3 million for construction and GMP development.
NexMed (America) Limited leases 1,000 square feet of office space in
Mississauga, Ontario, Canada for $800 per month pursuant to a month-to-month
arrangement.
NexMed International Limited subleases 1,000 square feet of office space
in Hong Kong for $3,000 per month pursuant to a month-to-month arrangement.
ITEM 3. LEGAL PROCEEDINGS.
There are no material legal proceedings pending against NexMed.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
There was no submission of matters to a vote of security holders.
PART II.
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.
Our Common Stock is traded on the NASDAQ National Market System (the
"NASDAQ") under the symbol "NEXM."
The following table sets forth the range of the high and low sales prices
as reported by the NASDAQ for the period from January 1, 2001 to December 31,
2002.
Price of
Common Stock ($)
----------------
High Low
Fiscal Year Ended December 31, 2001 ------- ------
First Quarter 10.6250 3.5000
Second Quarter 6.8800 3.7000
Third Quarter 5.4900 1.5500
Fourth Quarter 3.7000 2.1500
Fiscal Year Ended December 31, 2002
First Quarter 5.1500 2.1000
Second Quarter 5.2500 2.3000
Third Quarter 2.7300 1.5400
Fourth Quarter 1.9900 0.3500
9
On March 24, 2003, the last reported sales price for our Common Stock on
the NASDAQ was $1.36 per share, and we had 219 holders of record of our Common
Stock.
DIVIDENDS
We have never paid cash dividends and do not have any plans to pay cash
dividends in the foreseeable future. Our board of directors anticipates that any
earnings that might be available to pay dividends will be retained to finance
our business.
RECENT SALES OF UNREGISTERED SECURITIES
None.
ITEM 6. SELECTED FINANCIAL DATA.
The following selected financial information is qualified by reference
to, and should be read in conjunction with, the Company's consolidated financial
statements and the notes thereto, and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" contained elsewhere herein.
2002 2001 2000 1999 1998
INCOME STATEMENT DATA
- ---------------------
Revenue
Product Sales $27,851 $56,309 0 $1,491,746 $5,709,083
Royalties $120,177 $11,780 0 0 0
Net Loss $(27,641,519) $(16,174,861) $(8,720,553) $(2,490,600) $(4,779,002)
Basic and Diluted Loss per Share $(1.03) $(0.63) $(0.40) $(0.18) $(0.64)
Weighted Average Common Shares
Outstanding Used for Basic and Diluted
Loss per Share 26,937,200 25,486,465 21,868,267 13,724,052 7,505,588
BALANCE SHEET DATA
- ------------------
Total Assets $14,140,127 $27,314,713 $39,989,682 $7,633,333 $5,924,628
Total Liabilities $10,916,635 $3,206,848 $1,245,507 $723,594 $7,594,067
Stockholders' Equity $3,223,492 $24,107,865 $38,744,175 $6,909,739 $(2,390,437)
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
GENERAL
Currently, we are focusing our efforts on application of the NexACT(R)
technology to developing the Alprox-TD(R) and Femprox(R) creams. We are also
exploring the application of the NexACT(R) technology to other drug compounds
and working on the development of new topical treatments for nail fungus,
premature ejaculation, urinary incontinence, wound healing, and the prevention
of nausea and vomiting associated with post-operative surgical procedures and
cancer chemotherapy.
We intend to (1) pursue our research, development, and marketing
activities and capabilities, both domestically and internationally, with regard
to our proprietary pharmaceutical products and (2) execute a business strategy
with the goal of achieving a level of development sufficient to enable us to
attract potential strategic partners with resources sufficient to further
develop and market our proprietary products.
10
CRITICAL ACCOUNTING ESTIMATES
Financial Reporting Release No. 60, which was recently released by the
Securities and Exchange Commission, requires all companies to include a
discussion of critical accounting policies or methods used in the preparation of
financial statements. Note 2 in the Notes to the Condensed Consolidated
Financial Statements, includes a summary of the significant accounting policies
and methods used in the preparation of our Consolidated Financial Statements.
Our discussion and analysis of our financial condition and results of
operations is based upon our consolidated financial statements, which have been
prepared in accordance with accounting principles generally accepted in the
United States of America. The preparation of these financial statements requires
our management to make estimates and assumptions that affect the reported
amounts of assets, liabilities, revenues and expenses, and related disclosure of
contingent assets and liabilities. Our accounting policies affect our more
significant judgments and estimates used in the preparation of its financial
statements. Actual results could differ from these estimates. The following is a
brief description of the more significant accounting policies and related
estimate methods that we follow:
Revenue recognition -- Revenues from product sales are recognized upon
delivery of products to customers, less allowances for returns and discounts.
Royalty revenue is recognized upon the sale of the related products, provided
the royalty amounts are fixed or determinable and the amounts are considered
collectible. Revenues earned under research contracts are recognized in
accordance with the cost-to-cost method outlined in Staff Accounting Bulletin
No. 101 whereby the extent of progress toward completion is measured on the
cost-to-cost basis; however, revenue recognized at any point will not exceed the
cash received. When the current estimates of total contract revenue and contract
cost indicate a loss, a provision for the entire loss on the contract is made.
Critical Estimate: In calculating the progress made toward completion of
a research contract, we must compare costs incurred to date to the total
estimated cost of the project. We estimate the cost of any given project based
on our past experience in product development as well as the past experience of
our research staff in their areas of expertise. Underestimating the total cost
of a research contract may cause us to accelerate the revenue recognized under
such contract. Conversely, overestimating the cost may cause us to delay revenue
recognized.
Long-lived assets -- We review for the impairment of long-lived assets
whenever events or circumstances indicate that the carrying amount of an asset
may not be recoverable. An impairment loss would be recognized when estimated
undiscounted future cash flows expected to result from the use of the asset and
its eventual disposition are less than its carrying amount. If such assets are
considered impaired, the amount of the impairment loss recognized is measured as
the amount by which the carrying value of the asset exceeds the fair value of
the asset, fair value being determined based upon discounted cash flows or
appraised values, depending on the nature of the asset. We have not identified
any such impairment losses.
Critical Estimate: Estimated undiscounted future cash flows are based on
sales projections for our products under development for which the long-lived
assets are used. In 2002, we performed a review for impairment of our
manufacturing facility based on projections of sales of our product candidates,
for which the facility is anticipated to be ultimately utilized. Overestimating
the future cash flows resulting from the commercialization of Alprox TD(R) may
lead to overstating the carrying value of the manufacturing facility by not
identifying an impairment loss.
Income Taxes -- In preparing our financial statements, we make estimates
of our current tax exposure and temporary differences resulting from timing
differences for reporting items for book and tax purposes. We recognize deferred
taxes by the asset and liability method of accounting for income taxes. Under
the asset and liability method, deferred income taxes are recognized for
differences between the financial statement and tax bases of assets and
liabilities at enacted statutory tax rates in effect for the years in which the
differences are expected to reverse. The effect on deferred taxes of a change in
tax rates is recognized in income in the period that includes the enactment
date. In addition, valuation allowances are established when necessary to reduce
deferred tax assets to the amounts expected to be realized.
Critical Estimate: In consideration of our accumulated losses and lack of
historical ability to generate taxable income to utilize our deferred tax
assets, we have estimated that we will not be able to realize any benefit from
our temporary differences and have recorded a full valuation allowance. If we
become profitable in the future at levels
11
which cause management to conclude that it is more likely than not that we will
realize all or a portion of the net operating loss carry-forward, we would
immediately record the estimated net realized value of the deferred tax asset at
that time and would then provide for income taxes at a rate equal to our
combined federal and state effective rates, which would be approximately 40%
under current tax laws. Subsequent revisions to the estimated net realizable
value of the deferred tax asset could cause our provision for income taxes to
vary significantly from period to period.
COMPARISON OF RESULTS OF OPERATIONS BETWEEN THE YEAR ENDED DECEMBER 31, 2002 AND
2001.
Revenues. We recorded revenues of $148,028 during the twelve months of
operations in 2002 as compared to $68,089 during the same period in 2001. The
revenues were comprised of royalty payments and payments for the sale of
manufacturing supplies in connection with the sale of Befar(R) in Asia, and from
the first milestone payment received from our Japanese research and development
partner. The 2002 sales of Befar(R) in China were lower than previously
anticipated. Befar(R), along with the currently approved oral erectile
dysfunction product, are currently classified in China as controlled substances,
and their distribution is limited to prescription by certain urologists and
dispensing through hospitals. Since Befar(R) is not yet approved in larger
western or Japanese markets, the lack of comparable clinical and physician
experiences as compared to the oral dosage form, may also contribute to a lower
physician prescription and patient demand for Befar(R). However, for 2003, our
Asian licensee anticipates that new and additional marketing campaigns and the
availability of US clinical data will increase awareness among patients and
physicians.
Cost of Products Sold. Our cost of products sold was $27,030 and $45,051
for 2002 and 2001 respectively, and is attributable to our cost for the
manufacturing supplies sold to our Asian licensee for the production of Befar(R)
in China. Our Asian licensee had sufficient inventory of the manufacturing
supplies during 2002 and made fewer purchases from us.
Research and Development Expenses. Our research and development expenses
for 2002 and 2001 were $21,615,787 and $12,456,384, respectively. Research and
development expenses attributable to Alprox-TD(R) and Femprox(R) in 2002 were
approximately $15,835,000 and $642,000, respectively, as compared to
approximately $6,968,000 and $993,000 in 2001. The increase in research and
development expenses is approximately 90% attributable to the pre-clinical and
clinical expenses for Alprox-TD(R), with the remaining increase in expenses
attributable to additional research and development personnel for the first ten
months of 2002, , and the increased depreciation for scientific equipment in our
facilities in New Jersey and Kansas and depreciation for the expansion of our
facilities in Robbinsville and in Princeton, NJ. In 2003, we expect that total
research and development spending will decrease with the completion of the two
Phase 3 pivotal studies for Alprox-TD(R). We anticipate increasing our efforts
and resources in the application of the NexACT(R) technology to other drug
compounds and delivery systems for the development of new products. We
anticipate that our expense requirements for research and development will not
increase in 2003. However, given our current level of cash reserves, we will not
be able to fund the development of our products unless we raise additional cash
reserves through financing from the sale of our securities or through entering
into partnering agreements. If we are successful in entering partnering
agreements for our products under development, we expect to receive milestone
payments, which we anticipate will offset some of our research and development
expenses.
Selling, General and Administrative Expenses. Our general and
administrative expenses were $6,065,347 during 2002 as compared to $4,770,021
during 2001. The increase is approximately 35% attributable to additional
expenses for legal and accounting fees related to SEC matters and other
operational activities, approximately 35% to educational grants and industry
conferences and the remaining increase in expenses for the expansion of investor
and shareholder relations programs. We expect that total general and
administrative spending in 2003 will decrease with the reduction in expenditures
and non-essential personnel, which we implemented in November 2002.
Other Income and Expense. Our other expense during 2002 was $81,008 as
compared to $174,785 for 2001. The decrease is a result of a charge for disposal
of fixed assets in 2001 of approximately $112,000 related to abandoned
equipment. There was no charge for the disposal of fixed assets in 2002.
Interest Income and Expense. We recognized $243,020 in net interest
expense during 2002 as compared to $1,203,291 in net interest income during
2001. The decrease is the result of a significant reduction in our cash
position,
12
lower interest rates in the current period, and an increase in
interest expense due to borrowings under our GE Capital facility and the
convertible notes issued in June 2002.
Benefit from Income taxes. In 2002, we were approved by the State of New
Jersey to sell a portion of our state tax credits pursuant to the Technology Tax
Certificate Transfer Program. We had approximately $1.65 million in NJ tax
credits, and were approved to sell $279,000 in 2002. We received proceeds of
$242,645 in 2002 as a result of the sale of the tax credits.
Net Loss. The net loss was $(27,641,519) or a loss of $(1.03) per share
for 2002, compared with $(16,174,861) or a loss of $(0.63) per share for 2001.
The increase in net loss is primarily attributable to the acceleration of U.S.
development activities including U.S. clinical studies and the increase to our
infrastructure to support these activities. We also used our resources to fund
ongoing operations and finance the construction of additional research and
development and manufacturing facilities. We also incurred expenses for the
reduction in non-essential personnel in November 2002.
COMPARISON OF RESULTS OF OPERATIONS BETWEEN THE YEAR ENDED DECEMBER 31, 2001 AND
2000.
Revenues. We recorded revenues of $68,089 during the twelve months of
operations in 2001 as compared to no revenue during the same period in 2000. The
revenues were royalty payments and payments for the sale of manufacturing
supplies in connection with the limited introduction of Befar(R) in China.
Cost of Products Sold. Our cost of products sold was $45,051 and zero in
2001 and 2000, respectively and is attributable to our cost for the
manufacturing supplies sold to our Asian licensee for the production of Befar(R)
in China.
Research and Development Expenses. Our research and development expenses
for 2001 and 2000 were $12,456,384 and $6,892,283, respectively. Research and
development expenses attributable to Alprox-TD(R) and Femprox(R) in 2001 were
approximately $6,968,000 and $993,000, respectively, as compared to
approximately $5,145,000 and $749,000 in 2000. The increase in research and
development expenses is attributable to the pre-clinical and clinical expenses
for Alprox-TD(R) and Femprox(R), additional research and development personnel,
increased legal fees incurred related to our intellectual property estate, and
the increased depreciation for scientific equipment in our facilities in New
Jersey and Kansas and amortization for the expansion of our facility in
Robbinsville, NJ.
Selling, General and Administrative Expenses. Our general and
administrative expenses were $4,770,021 during 2001 as compared to $3,209,465
during 2000. The increase is largely attributable to additional personnel in our
Corporate Affairs, Finance, Human Resource, Information Technology and
Commercial Development departments. We also incurred additional expenses for
professional fees related to tax, human resource development, commercial
development, public relations and SEC matters; amortization for leasehold
improvements; and expansion of investor and shareholder relations programs.
Interest Income and Expense. We recognized $1,203,291 in net interest
income during 2001, compared with a net interest income of $1,255,450 during
2000. The decrease is a result of the drop in interest rates and a reduction in
our cash position.
Net Loss. The net loss was $(16,174,861) or a loss of $(0.63) per share
for 2001, compared with $(8,720,553) or a loss of $(0.40) per share for 2000.
The increase in net loss is primarily attributable to the acceleration of U.S.
development activities including U.S. clinical studies and the increase to our
infrastructure to support these activities. We also used our resources to fund
ongoing operations and finance the construction of additional research and
development and manufacturing facilities.
13
QUARTERLY RESULTS
The following table sets forth selected quarterly financial information
for the years ended December 31, 2001 and 2002. The operating results are not
necessarily indicative of results for any future period.
Three Months Ended (in thousands, except per share data)
- --------------------------------------------------------------------------------------------------------------------------
March 31, 2002 June 30, 2002 September 30, 2002 December 31, 2002
- --------------------------------------------------------------------------------------------------------------------------
Total Revenues $45 $22 $78 $3
- --------------------------------------------------------------------------------------------------------------------------
Gross Profit -- -- -- --
- --------------------------------------------------------------------------------------------------------------------------
Loss from Operations (5,637) (6,925) (6,743) (8,255)
- --------------------------------------------------------------------------------------------------------------------------
Net Loss (5,579) (6,941) (6,875) (8,247)
- --------------------------------------------------------------------------------------------------------------------------
Basic & Diluted Loss $(0.22) $(0.27) $(0.24) $(0.30)
Per Share
- --------------------------------------------------------------------------------------------------------------------------
March 31, 2001 June 30, 2001 September 30, 2001 December 31, 2001
- --------------------------------------------------------------------------------------------------------------------------
Total Revenues $-- $-- $-- $68
- --------------------------------------------------------------------------------------------------------------------------
Gross Profit -- -- -- --
- --------------------------------------------------------------------------------------------------------------------------
Loss from Operations (3,647) (3,813) (3,678) (6,064)
total is off $1 due to
rounding
- --------------------------------------------------------------------------------------------------------------------------
Net Loss total is off $1 (3,212) (3,588) (3,457) (5,917)
due to rounding
- --------------------------------------------------------------------------------------------------------------------------
Basic & Diluted Loss $(0.13) $(0.14) $(0.14) $(0.23)
Per Share
- --------------------------------------------------------------------------------------------------------------------------
LIQUIDITY AND CAPITAL RESOURCES
We have experienced net losses and negative cash flow from operations
each year since our inception. Through December 31, 2002, we had an accumulated
deficit of $67,987,969. Our operations have principally been financed through
private placements of equity securities and debt financing. Funds raised in past
periods should not be considered an indication of our ability to raise
additional funds in future periods.
At December 31, 2002, we had cash and cash equivalents, certificates of
deposit and investments in marketable securities of approximately $1.57 million
as compared to $18.74 million at December 31, 2001. As a result of the FDA
decision in November 2002, we implemented a cash conservation program, which
included a significant reduction in expenses and non-essential personnel and
allocated our remaining our cash reserves for our operational requirements at
the reduced level.
As a result of our losses to date, working capital deficiency and
accumulated deficit, our independent accountants have concluded that there is
substantial doubt as to our ability to continue as a going concern for a
reasonable period of time, and have modified their report in the form of an
explanatory paragraph describing the events that have given rise to this
uncertainty. Our continuation is based on our ability to generate or obtain
sufficient cash to meet our obligations on a timely basis and ultimately to
attain profitable operations. Our independent auditors' going concern
qualification may make it more difficult for us to obtain additional funding to
meet our obligations.
In January and February 2003, we issued two short-term promissory notes,
which totaled $600,000, to one accredited investor. These promissory notes bore
interest at 12% per annum and were convertible at the noteholder's option, into
our securities at such time as we close a private placement of our securities.
On March 21, 2003, we closed a private placement of shares of our common stock
at $1.50 per share. For each share purchased, the investors received a 3-year
warrant to purchase three-quarters (3/4) of a share of common stock at an
exercise price of $2.00 per share. The noteholder elected to convert the
outstanding $614,064 in principal and interest due into 409,376 shares of our
common stock and 307,032 warrants to purchase shares of our common stock.
Pursuant to the private placement agreement, we issued a total of 209,987 shares
and 157,490 three-year warrants to purchase shares of our common stock at $2.00
per share to three accredited investors and received approximately $314,000 in
gross proceeds.
On February 4, 2003, we raised $533,489 in interim financing from the
exercise of 389,408 warrants to purchase shares of our common stock at an
exercise price of $1.37 per share. The warrants exercised were issued in 2002 in
connection with the issuance of convertible notes secured by a mortgage on our
manufacturing facility in East Windsor, NJ. In exchange for the early exercise
of these warrants, we agreed to reduce the conversion price of the convertible
notes from $4.08 to $2.75 per share. (Notes 5 and 15 in the Notes to the
Consolidated Financial Statements).
14
In March 2003, we issued one short-term promissory note for $500,000 to
one accredited investor. This promissory note, which is due on May 4, 2003,
bears interest at 15% per annum and provides for two-year warrants to purchase
50,000 shares of our common stock, at an exercise price of $2.00 per share.
As of March 24, 2003, we had approximately $400,000 of cash and our
average monthly burn rate is currently $600,000 per month, so we have sufficient
cash for a period of approximately three weeks. We are in discussions with
various parties for financing, which we anticipate will close in April. However,
if we cannot obtain such additional financing of at least $3 million, in the
short term, we will have to scale-back or discontinue our existing operations
and may not be able to continue the development of even our Alprox-TD(R)
product.
To date, we have spent approximately $60.6 million on the Alprox-TD(R)
development program, and anticipate that through NDA submission during half of
2004, we will require an additional $15 million. Given our current level of cash
reserves, we will not be able to fund the development of Alprox-TD(R) through
the NDA submission unless we raise additional cash reserves through financing or
partnering agreements. If we are successful in entering into partnering
agreements for Alprox-TD(R), we anticipate that we will receive significant
milestone payments, which we will use to pay for the projected development
expenses through the NDA submission, including the open label study of
Alprox-TD(R). If we are not able to enter into a licensing agreement for
Alprox-TD(R), we believe that we will have to discontinue the development of
this product. Since we cannot predict the actions of the FDA, the level of other
research and development activities we may be engaged in, and our ability to
enter into partnering agreements, we cannot accurately predict the expenditure
required for the period between NDA submission of Alprox-TD(R) and its
commercialization.
We have spent approximately $7.5 million in total for the land, building
and GMP development related to our East Windsor manufacturing facility and
estimate that we will spend an additional $500,000 prior to completion of GMP
compliance development for the facility. To date, we have spent $7.5 million on
the Femprox and other NexACT-based development programs, and $1.3 million for
the Viratrol device. We intend to initiate additional research and development
activities for these products pending the availability of financing or through
partnering arrangements.
At December 31, 2002, we recorded significantly less non-cash
compensation expense than in 2001 as a result of a reduction in the number of
stock options granted to consultants and non-employee directors and the full
amortization of stock options previously granted to consultants and non-employee
directors. During 2002, we recorded an amortization of debt discount due to the
issuance of the convertible notes in June 2002, and we had an increase in debt
issuance cost as a result of the issuance of such notes.
We lease office space and research facilities under operating lease
agreements expiring through 2005. We also lease equipment from GE Capital under
a capital lease expiring through 2006 (Note 13 of the Consolidated Financial
Statements). Future minimum payments under noncancellable operating and capital
leases with initial or remaining terms of one year or more, consisted of the
following at December 31, 2002:
OPERATING CAPITAL
2003 $488,114 $741,017
2004 132,964 741,017
2005 27,759 432,655
2006 3,150 39,278
2007 2,100 --
-------- ----------
Total minimum lease payments $654,087 1,953,967
--------
Less: amount representing interest (242,080)
Present value of future minimum lease payments 1,711,887
Less: current portion (609,676)
----------
Capital lease obligations, net of current portion $1,102,211
----------
15
On June 11, 2002, the Company issued a convertible note (the "Note")
with a face value of $5 million to two purchasers. The Note is payable on
November 30, 2005 and is collateralized by the Company's manufacturing facility
in East Windsor, New Jersey. The Note was initially convertible into shares of
the Company's common stock at a conversion price initially equal to $4.08 per
share (1,225,490 shares). The purchasers also received warrants to purchase
389,408 shares of common stock (the "Warrants") at an exercise price equal to
the conversion price of the Note and a term of five years from the date of
issuance. On February 4, 2003 the terms of the convertible notes were amended.
In order to induce the holders to exercise the Warrants in full, the Company
agreed to reduce the conversion price under the notes and the exercise price of
the Warrants. The note is now convertible into the company's common stock at a
conversion price of $2.75 per share and the warrant exercise price was reduced
to $1.37. Pursuant to the amendment, all of the Warrants were exercised on
February 4, 2003 and the Company received proceeds of $533,489 from such
exercise. The issuance of shares of the Company's common stock on March 21, 2003
resulted in a further reduction of the conversion price of the Note to $2.72. If
the Company were to issue additional shares of its common stock at per share
prices lower than the conversion price of the Note, the conversion price may be
adjusted lower. Interest accretes on the Note on a semi-annual basis at a rate
of 5% per annum, and the Company may pay such amounts in cash or by effecting
the automatic conversion of such amount into the Company's common stock at a 10%
discount to the then average market prices. Subject to certain exceptions, the
Company has prepayment rights for portions of the principal amount, payable in
cash or by conversion into common stock at a 10% discount to average market
prices.
In February 2001, the Company entered into a financial arrangement with
GE Capital Corporation for a line of credit, which provided for the financing of
up to $5 million of equipment (i) for its new East Windsor, NJ manufacturing
facility and (ii) for its expanded corporate and laboratory facilities in
Robbinsville, NJ. Equipment financed through this facility has been in the form
of a 42-month capital lease. As of December 31, 2002, the Company had financed
$1,113,459 of equipment purchases under the GE credit line. The $5 million
credit line expired in March 2002, and as of December 31, 2002, there was an
outstanding balance due GE of $724,577 under this facility. This balance is
payable in monthly installments through various dates in 2004.
In January 2002, GE approved a new credit line, which provides for the
financing of up to $3 million of equipment and expires on December 31, 2002.
During 2002, the Company accessed $1,111,427 of the credit line. As of December
31, 2002, when the January 2002 facility expired, there was an outstanding
balance due GE of $987,310 under this facility. Balances due are payable in 42
monthly installments from date of takedown.
RECENT ACCOUNTING PRONOUNCEMENTS
Statement of Financial Accounting Standards (SFAS) No. 141, "Business
Combinations," establishes accounting and reporting for business combinations by
requiring that all business combinations be accounted for under the purchase
method. Use of the pooling-of-interests method is no longer permitted. SFAS 141
requires that the purchase method be used for business combinations initiated
after June 30, 2001. The adoption of SFAS 141 did not have a material impact on
the Company's financial condition or results of operations.
SFAS No. 142, "Goodwill and Other Intangible Assets," requires that
goodwill no longer be amortized to earnings, but instead be reviewed for
impairment. The Company adopted SFAS 142 effective January 1, 2002. The adoption
of SFAS 142 did not have a material impact on the Company's financial condition
or results of operations.
In August 2001, Financial Accounting Standards (FAS) No. 144, "Accounting
for the Impairment or Disposal of Long-Lived Assets," was issued, replacing FAS
No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived
Assets to Be Disposed Of," and portions of APB Opinion 30, "Reporting the
Results of Operations." FAS 144 provides a single accounting model for
long-lived assets to be disposed of and changes the criteria that would have to
be met to classify an asset as held-for-sale. FAS 144 retains the requirement of
APB Opinion 30, to report discontinued operations separately from continuing
operations and extends that reporting to a component of an entity that either
has been disposed of or is classified as held for sale. FAS 144 is effective
January 1, 2002 for the Company. The adoption of FAS 144 did not have a material
impact on the Company's financial condition or results of operations.
In July 2002, the FASB issued Statement of Financial Accounting Standards
No. 146 (SFAS 146) "Accounting for Costs Associated with Exit or Disposal
Activities." SFAS 146 requires companies to recognize costs associated with exit
or disposal activities when they are incurred rather than at the date of a
commitment to an exit or disposal plan as
16
was the case in prior guidance by EITF Issue No. 94-3, "Liability Recognition
for Certain Employee Termination Benefits and Other Costs to Exit an Activity
(including Certain Costs Incurred in a Restructuring)." SFAS 146 replaces EITF
Issue No. 94-3. SFAS 146 is effective for exit or disposal activities initiated
after December 31, 2002. The Company will adopt the provisions of SFAS 146 as of
January 1, 2003.
In December 2002, the SFASB issued Statement of Financial Accounting
Standards No. 148 ("SFAS 148"), Accounting for Stock-Based
Compensation-Transition and Disclosure. SFAS 148 amends SFAS No. 123, Accounting
for Stock-Based Compensation, to provide alternative methods of transition for a
voluntary change to the fair value based method of accounting for stock-based
employee compensation. In addition, SFAS 148 amends the disclosure requirements
of SFAS 123 to require prominent disclosures in both annual and interim
financial statements about the method of accounting for stock based employee
compensation and the effect of the method used on reported results. The
provisions of SFAS 148 are effective for financial statements for fiscal years
and interim periods ending after December 15, 2002. The disclosure provisions of
SFAS 148 have been adopted by the Company (see Note 2 of the Notes to
Consolidated Financial Statements). SFAS 148 did not require the Company to
change to the fair value based method of accounting for stock-based
compensation.
In November 2002, the SFASB issued Interpretation No. 45, "Guarantor's
Accounting and Disclosure Requirements for Guarantees, Including Indirect
Guarantees of Indebtedness of Others" (FIN 45). FIN 45 requires at the time a
company issues a guarantee, the Company must recognize an initial liability for
the fair market value of the obligations it assumes under that guarantee and
must disclose that information in its interim and annual financial statements.
The initial recognition and measurement provisions are effective on a
prospective basis to guarantees issued or modified after December 31, 2002. The
adoption of this Interpretation is not expected to have a material effect on the
Company's consolidated financial statements.
In January 2003, the SFASB issued Interpretation No. 46 "Consolidation of
Variable Interest Entities" (FIN 46). Variable Interest Entities ("VIEs") are
entities where control is achieved through means other than voting rights. FIN
46 provides guidance on the identification of and financial reporting for VIEs.
A VIE is required to be consolidated if the company is subject to the majority
of the risk of loss from the VIE's activities or is entitled to receive a
majority of the entity's residual returns, or both. The consolidation
requirements for VIEs created after January 31, 2003 are effective immediately
and consolidation requirements apply to existing entities in the first fiscal
year or interim period beginning after June 15, 2003. The adoption of this
Interpretation is not expected to have a material effect on the Company's
consolidated financial statements.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
We do not hold derivative financial investments, derivative commodity
investments, engage in foreign currency hedging or other transactions that
expose us to material market risk.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
INDEX TO FINANCIAL STATEMENTS
PAGE
REPORT OF INDEPENDENT ACCOUNTANTS 18
FINANCIAL STATEMENTS
Consolidated Balance Sheets -
December 31, 2002 and 2001 19
Consolidated Statement of Operations and
Comprehensive loss for the years ended
December 31, 2002, 2001 and 2000 20
Consolidated Statement of Changes in
Stockholders' Equity for years ended
December 31, 2002, 2001 and 2000 21
Consolidated Statement of Cash Flows for
the years ended December 31, 2002, 2001
and 2000 22
NOTES TO FINANCIAL STATEMENTS 23
17
REPORT OF INDEPENDENT ACCOUNTANTS
To the Board of Directors and Stockholders of NexMed, Inc.
In our opinion, the accompanying consolidated balance sheets and the related
consolidated statements of operations and comprehensive loss, of changes in
stockholders' equity and of cash flows present fairly, in all material respects,
the financial position of NexMed, Inc. and its subsidiaries at December 31, 2002
and 2001, and the results of their operations and their cash flows for each of
the three years in the period ended December 31, 2002 in conformity with
accounting principles generally accepted in the United States of America. These
financial statements are the responsibility of the Company's management; our
responsibility is to express an opinion on these financial statements based on
our audits. We conducted our audits of these statements in accordance with
auditing standards generally accepted in the United States of America, which
require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement. An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, and evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
The accompanying financial statements have been prepared assuming the Company
will continue as a going concern. As discussed in Note 1 to the financial
statements, the Company has suffered recurring losses and negative cash flows
from operations, has a deficit in working capital and expects to incur future
losses. These factors raise substantial doubt about the Company's ability to
continue as a going concern. Management's plans in regard to those matters are
also described in Note 1. The accompanying financial statements do not include
any adjustments that might result from the outcome of this uncertainty.
PricewaterhouseCoopers LLP
New York, New York
February 25, 2003, except as to Note 15
which is as of March 21, 2003
18
NEXMED, INC.
CONSOLIDATED BALANCE SHEETS
- --------------------------------------------------------------------------------
DECEMBER 31,
ASSETS 2002 2001
Current assets
Cash and cash equivalents $ 1,035,149 $ 12,913,803
Certificates of deposit -- 3,564,373
Marketable securities 539,795 2,265,529
Notes Receivable, current 198,348 --
Prepaid expenses and other current assets 498,042 879,491
------------ ------------
TOTAL CURRENT ASSETS 2,271,334 19,623,196
Fixed assets, net 11,507,564 7,691,517
Note Receivable 48,341 --
Debt Issuance cost, net of accumulated
amortization of $57,575 312,888 --
------------ ------------
TOTAL ASSETS $ 14,140,127 $ 27,314,713
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable and accrued expenses $ 4,874,441 $ 2,194,730
Capital lease obligation 609,676 287,541
------------ ------------
TOTAL CURRENT LIABILITIES 5,484,117 2,482,271
Long term liabilities
Convertible note payable 4,330,307 --
Capital lease obligations, net of 1,102,211 724,577
current portion
------------ ------------
TOTAL LIABILITIES 10,916,635 3,206,848
------------ ------------
Commitments and contingincies (Note 13)
Stockholders' equity:
Preferred stock $.001 par value,
10,000,000 shares authorized,
none issued and outstanding -- --
Common stock, $.001 par value,
80,000,000 shares authorized,
28,293,719 and 25,541,934 shares 28,294 25,542
issued and outstanding, respectively
Additional paid-in capital 71,381,751 64,538,838
Accumulated other comprehensive income (101,022) (103,361)
Accumulated deficit (67,987,969) (40,346,450)
------------ ------------
3,321,054 24,114,569
Less: Deferred compensation (97,562) (6,704)
------------ ------------
TOTAL STOCKHOLDERS' EQUITY 3,223,492 24,107,865
------------ ------------
TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY $ 14,140,127 $ 27,314,713
============ ============
The accompanying notes are an integral part of these financial statements.
19
NEXMED, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
- --------------------------------------------------------------------------------
FOR THE YEAR ENDED
DECEMBER 31,
2002 2001 2000
Revenue
Product sales $ 27,851 $ 56,309 $ --
License fees 120,177 11,780 --
------------ ------------ ------------
Total revenue 148,028 68,089 --
------------ ------------ ------------
Costs and expenses
Cost of products sold 27,030 45,051 --
Research and development 21,615,787 12,456,384 6,892,283
Selling, general and administrative 6,065,347 4,770,021 3,209,465
------------ ------------ ------------
TOTAL COSTS AND EXPENSES 27,708,164 17,271,456 10,101,748
------------ ------------ ------------
Loss from operations (27,560,136) (17,203,367) (10,101,748)
------------ ------------ ------------
Other income (expense)
Other Income (expense) (81,008) (174,785) 125,745
Interest income 141,266 1,236,845 1,255,450
Interest expense (384,286) (33,554) --
------------ ------------ ------------
Total other income (expense) (324,028) 1,028,506 1,381,195
------------ ------------ ------------
Loss before benefit from income taxes (27,884,164) (16,174,861) (8,720,553)
Benefit from income taxes 242,645 -- --
------------ ------------ ------------
NET LOSS (27,641,519) (16,174,861) (8,720,553)
Other comprehensive loss
Foreign currency translation adjustments (223) 36 207
Unrealized gain (loss) on marketable securities 2,562 6,006 (109,725)
------------ ------------ ------------
COMPREHENSIVE LOSS $(27,639,180) $(16,168,819) $ (8,830,071)
------------ ------------ ------------
Basic and diluted loss per share $ (1.03) $ (.63) $ (.40)
------------ ------------ ------------
Weighted average common shares outstanding
used for basic and diluted loss per share 26,937,200 25,486,465 21,868,267
------------ ------------ ------------
The accompanying notes are an integral part of these financial statements.
20
NEXMED, INC.
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
- --------------------------------------------------------------------------------
COMMON COMMON ADDITIONAL
STOCK STOCK PAID-IN ACCUMULATED
(SHARES) (AMOUNT) CAPITAL DEFICIT
---------- ------------ ------------ ------------
Balance at January 1, 2000 16,127,134 $ 16,127 $ 22,356,112 $(15,451,036)
Issuance of common stock and warrants for cash 4,044,756 4,045 28,404,386 --
Issuance of common stock upon exercise of warrants, net 4,973,494 4,973 12,175,055 --
Issuance of common stock for services 2,000 2 7,998 --
Issuance of compensatory options to consultants -- -- 65,610 --
Amortization of deferred compensation expense -- -- -- --
Unrealized gain from available-for-sale securities -- -- -- --
Cumulative translation adjustment -- -- -- --
Net loss -- -- -- (8,720,553)
---------- ------------ ------------ ------------
Balance at December 31, 2000 25,147,384 25,147 63,009,161 (24,171,589)
Issuance of common stock
upon exercise of stock options 189,550 190 382,010 --
Issuance of common stock
upon exercise of warrants, net 200,000 200 599,800 --
Issuance of common stock for services 5,000 5 27,495 --
Issuance of compensatory options and warrants to consultants -- -- 482,770 --
Capital contribution -- -- 37,602 --
Amortization of deferred compensation expense -- -- -- --
Unrealized loss from available-for-sale securities -- -- -- --
Cumulative translation adjustment -- -- -- --
Net loss -- -- -- (16,174,861)
---------- ------------ ------------ ------------
Balance at December 31, 2001 25,541,934 25,542 64,538,838 (40,346,450)
Issuance of common stock
from private placement, net of commission paid 2,666,670 2,667 5,729,204 --
Issuance of common stock
upon exercise of stock options 53,000 53 18,447 --
Issuance of compensatory options and warrants to consultants -- -- 71,840 --
Issuance of common stock to Board of Directors 32,115 32 56,468 --
Issuance of common stock to employees as bonus -- -- 104,392 --
Issuance of warrants as debt issuance cost -- -- 66,861 --
Discount on convertible note payable -- -- 795,701 --
Amortization of deferred compensation expense -- -- -- --
Unrealized loss from available-for-sale securities -- -- -- --
Cumulative translation adjustment -- -- -- --
Net loss -- -- -- (27,641,519)
---------- ------------ ------------ ------------
Balance at December 31, 2002 28,293,719 $ 28,294 $ 71,381,751 $(67,987,969)
---------- ------------ ------------ ------------
ACCUMULATED OTHER
COMPREHENSIVE INCOME
-------------------------------
UNREALIZED
FOREIGN LOSS ON TOTAL
DEFERRED CURRENCY MARKETABLE STOCKHOLDERS'
COMPENSATION TRANSLATION SECURITIES EQUITY
------------ ------------ ------------ ------------
Balance at January 1, 2000 $ (11,579) $ 115 $ -- $ 6,909,739
Issuance of common stock and warrants for cash -- -- -- 28,408,431
Issuance of common stock upon exercise of warrants, net -- -- -- 12,180,028
Issuance of common stock for services -- -- -- 8,000
Issuance of compensatory options to consultants -- -- -- 65,610
Amortization of deferred compensation expense 2,438 -- -- 2,438
Unrealized gain from available-for-sale securities -- -- (109,725) (109,725)
Cumulative translation adjustment -- 207 -- 207
Net loss -- -- -- (8,720,553)
------------ ------------ ------------ ------------
Balance at December 31, 2000 (9,141) 322 (109,725) 38,744,175
Issuance of common stock
upon exercise of stock options -- -- -- 382,200
Issuance of common stock
upon exercise of warrants, net -- -- -- 600,000
Issuance of common stock for services -- -- -- 27,500
Issuance of compensatory options and warrants to consultants -- -- -- 482,770
Capital contribution -- -- -- 37,602
Amortization of deferred compensation expense 2,437 -- -- 2,437
Unrealized loss from available-for-sale securities -- -- 6,006 6,006
Cumulative translation adjustment -- 36 -- 36
Net loss -- -- -- (16,174,861)
------------ ------------ ------------ ------------
Balance at December 31, 2001 (6,704) 358 (103,719) 24,107,865
Issuance of common stock
from private placement, net of commission paid -- -- -- 5,731,871
Issuance of common stock
upon exercise of stock options -- -- -- 18,500
Issuance of compensatory options and warrants to consultants -- -- -- 71,840
Issuance of common stock to Board of Directors (15,000) -- -- 41,500
Issuance of common stock to employees as bonus (78,294) -- -- 26,098
Issuance of warrants as debt issuance cost -- -- -- 66,861
Discount on convertible note payable -- -- -- 795,701
Amortization of deferred compensation expense 2,436 -- -- 2,436
Unrealized loss from available-for-sale securities -- -- 2,562 2,562
Cumulative translation adjustment -- (223) -- (223)
Net loss -- -- -- (27,641,519)
------------ ------------ ------------ ------------
Balance at December 31, 2002 $ (97,562) $ 135 $ (101,157) $ 3,223,492
------------ ------------ ------------ ------------
The accompanying notes are an integral part of these financial statements.
21
NEXMED, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
- --------------------------------------------------------------------------------
FOR THE YEAR ENDED
DECEMBER 31,
2002 2001 2000
Cash flows from operating activities
Net (loss) $(27,641,519) $(16,174,861) $ (8,720,553)
Adjustments to reconcile net loss to net cash
from operating activities
Depreciation and amortization 1,066,436 527,011 257,149
Non-cash compensation expense 491,874 512,707 76,048
Non-cash insurance expense (income) (2,155) 15,044 --
Net loss on sale of marketable securities 142,291 -- 8,812
Loss on disposal of property and equipment -- 112,687 --
Decrease in notes receivable -- -- 2,000,000
Decrease (increase) in prepaid expense and other assets 381,449 (77,019) (632,477)
Increase in accounts payable and accrued expenses 2,329,711 949,223 688,843
------------ ------------ ------------
NET CASH USED IN OPERATING ACTIVITIES (23,231,913) (14,135,208) (6,322,178)
------------ ------------ ------------
Cash flows from investing activities
Capital expenditures (3,587,473) (3,820,458) (3,309,957)
Issuance of loan receivable (309,575) -- --
Proceeds from collection of loan receivable 62,886 -- --
Purchases of certificates of deposits and marketable securities (3,610,747) (5,878,345) (23,368,745)
Proceeds from sale/redemption of certificates of deposits and
marketable securities 8,763,279 8,126,732 15,162,880
------------ ------------ ------------
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES 1,318,370 (1,572,071) (11,515,822)
------------ ------------ ------------
Cash flows from financing activities
(Decrease) increase in due to offices -- -- (33,092)
Issuance of common stock, net of offering costs 5,750,371 982,200 40,588,459
Return of gain on stock by former executive -- 37,602 --
Issuance of notes payable 4,696,399 -- --
Repayment of notes payable -- -- (133,838)
Principal payments on capital lease obligations (411,658) (101,341) --
------------ ------------ ------------
NET CASH PROVIDED BY FINANCING ACTIVITIES 10,035,112 918,461 40,421,529
------------ ------------ ------------
Effect of foreign exchange on cash (223) 36 207
------------ ------------ ------------
Net (decrease) increase in cash and cash equivalents (11,878,654) (14,788,782) 22,583,736
Cash and cash equivalents
Beginning of period 12,913,803 27,702,585 5,118,849
------------ ------------ ------------
End of period $ 1,035,149 $ 12,913,803 $ 27,702,585
------------ ------------ ------------
Cash paid for interest $ 196,955 $ 33,554 $ 10,413
Supplemental disclosure of non-cash investing and financing activities:
Property and equipment acquired through capital lease obligations $ 1,111,427 $ 1,113,459 $ --
The accompanying notes are an integral part of these financial statements.
22
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
1. ORGANIZATION AND BASIS OF PRESENTATION
The Company was incorporated in Nevada in 1987. In January 1994, the
Company began research and development of a device for the treatment of
herpes simplex. The Company, since 1995, has conducted research and
development both domestically and abroad on proprietary pharmaceutical
products, with the goal of growing through acquisition and development
of pharmaceutical products and technology.
The accompanying financial statements have been prepared on a basis
which contemplates the realization of assets and the satisfaction of
liabilities and commitments in the normal course of business. The
Company has an accumulated deficit of $67,987,969 at December 31, 2002,
a deficit in working capital, and expects that it will incur additional
losses in completing the research, development and commercialization of
its technologies. These circumstances raise substantial doubt about the
Company's ability to continue as a going concern. Management
anticipates that it will require additional financing, which it is
actively pursuing, to fund operations, including continued research,
development and clinical trials of the Company's product candidates.
Although management continues to pursue these plans, there is no
assurance that the Company will be successful in obtaining financing on
terms acceptable to the Company. If the Company is unable to obtain
additional financing, operations will need to be discontinued. The
financial statements do not include any adjustments that might result
from the outcome of this uncertainty.
2. SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES
Significant accounting principles followed by the Company in preparing
its financial statements are as follows:
PRINCIPLES OF CONSOLIDATION
The consolidated financial statements include the accounts of the
Company and its majority and wholly owned subsidiaries. All significant
intercompany transactions have been eliminated.
RECLASSIFICATIONS
Reclassifications of certain amounts for prior years have been recorded
to conform to the current year presentation.
TRANSLATION OF FOREIGN CURRENCIES
The functional currency of the Company's foreign subsidiaries, located
in Hong Kong and Canada, is the local currency. Assets and liabilities
of the Company's foreign subsidiaries are translated to United States
dollars based on exchange rates at the end of the reporting period.
Income and expense items are translated at average exchange rates
prevailing during the reporting period. Translation adjustments are
accumulated in a separate component of stockholder's equity.
Transaction gains or losses are included in the determination of
operating results.
CASH AND CASH EQUIVALENTS
For purposes of the statement of cash flows, cash equivalents represent
all highly liquid investments with an original maturity date of three
months or less.
MARKETABLE SECURITIES
Marketable securities consist of high quality corporate and government
securities, which have original maturities of more than three months at
the date of purchase and less than one year from the date of the
balance sheet, and equity investments in publicly-traded companies. The
Company classifies all debt securities and equity securities with
readily determinable market value as
23
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
"available for sale" in accordance with SFAS No. 115, "Accounting for
Certain Investments in Debt and Equity Securities." These investments
are carried at fair market value with unrealized gains and losses
reported as a separate component of stockholders' equity. Gross
unrealized losses were $103,359 and $120,956 for 2002 and 2001,
respectively. Gross realized gains from the sales of securities
classified as available for sale were $143,971, $263,052, and $9,653
for 2002, 2001 and 2000 respectively. Gross realized losses were
$1,680, $263,052, and $18,465 respectively. For the purpose of
determining realized gains and losses, the cost of securities sold was
based on specific identification. The Company reviews investments on a
quarterly basis for reductions in market value that are other than
temporary. When such reductions occur, the cost of the investment is
adjusted to its fair value through a charge to net income.
FAIR VALUE OF FINANCIAL INSTRUMENTS
The carrying value of cash and cash equivalents, notes payable and
accounts payable and accrued expenses approximates fair value due to
the relatively short maturity of these instruments.
FIXED ASSETS
Property and equipment are stated at cost less accumulated
depreciation. Depreciation of equipment and furniture and fixtures is
provided on a straight-line basis over the estimated useful lives of
the assets, generally three to ten years. Depreciation of buildings is
provided on a straight-line basis over its estimated useful life of 31
years. Amortization of leasehold improvements is provided on a
straight-line basis over the shorter of their estimated useful life or
the lease term. The costs of additions and betterments are capitalized,
and repairs and maintenance costs are charged to operations in the
periods incurred.
LONG-LIVED ASSETS
The Company reviews for the impairment of long-lived assets whenever
events or circumstances indicate that the carrying amount of an asset
may not be recoverable. An impairment loss would be recognized when
estimated undiscounted future cash flows expected to result from the
use of the asset and its eventual disposition is less than its carrying
amount. If such assets are considered impaired, the amount of the
impairment loss recognized is measured as the amount by which the
carrying value of the asset exceeds the fair value of the asset, fair
value being determined based upon discounted cash flows or appraised
values, depending on the nature of the asset. No such impairment losses
have been identified by the Company.
REVENUE RECOGNITION
Revenues from product sales are recognized upon delivery of products to
customers, less allowances for estimated returns and discounts. Royalty
revenue is recognized upon the sale of the related products, provided
the royalty amounts are fixed or determinable and the amounts are
considered collectible.
Revenues earned under research contracts are recognized in accordance
with the cost-to-cost method outlined in Staff Accounting Bulletin No.
101 whereby the extent of progress toward completion is measured on the
cost-to-cost basis; however, revenue recognized at any point will not
exceed the cash received. When the current estimates of total contract
revenue and contract cost indicate a loss, a provision for the entire
loss on the contract is made in the period which it becomes probable.
RESEARCH AND DEVELOPMENT
Research and development costs are expensed as incurred and include the
cost of salaries, building costs, utilities, allocation of indirect
costs, and expenses to third parties who conduct
24
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
research and development, pursuant to development and consulting
agreements, on behalf of the Company.
In August 2002, the Company entered into a research and development
agreement with a Japanese pharmaceutical company. Pursuant to the terms
of this agreement, the Company will develop a new tape/patch treatment
for urinary dysfunction which incorporates the Japanese partner's
proprietary drug compound with the NexACT(R) technology. The Company
recognized revenue of approximately $85,000 in 2002, with future
periodic payments to be made based on the achievement of certain
development milestones. The Company will also retain the right to
manufacture and commercialize the new product worldwide except in
Japan.
INCOME TAXES
Income taxes are accounted for under the asset and liability method.
Deferred income taxes are recorded for temporary differences between
financial statement carrying amounts and the tax bases of assets and
liabilities. Deferred tax assets and liabilities reflect the tax rates
expected to be in effect for the years in which the differences are
expected to reverse. A valuation allowance is provided if it is more
likely than not that some or all of the deferred tax assets will not be
realized.
LOSS PER COMMON SHARE
Basic earnings per share ("Basic EPS") is computed by dividing income
available to common stockholders by the weighted average number of
common shares outstanding during the period. Diluted earnings per share
("Diluted EPS") gives effect to all dilutive potential common shares
outstanding during the period. The computation of Diluted EPS does not
assume conversion, exercise or contingent exercise of securities that
would have an antidilutive effect on per share amounts.
At December 31, 2002, 2001 and 2000, outstanding options to purchase
4,750,755, 3,834,575, and 3,582,675 shares of common stock,
respectively, with exercise prices ranging from $.50 to $16.25 have
been excluded from the computation of diluted loss per share as they
are antidilutive. Outstanding warrants to purchase 2,044,908,
2,206,549, and 2,291,549 shares of common stock, respectively, with
exercise prices ranging from $1.00 to $16.20 have also been excluded
from the computation of diluted loss per share as they are
antidilutive. Promissory note convertible into 1,225,490 shares of
common stock (Note 5) has also been excluded from the computation of
diluted loss per share as it is antidilutive. In 2003, this note was
amended to be convertible into 1,818,182 shares of common stock (Note
15).
ACCOUNTING FOR STOCK BASED COMPENSATION
As provided by SFAS 123, Accounting for Stock-Based Compensation ("SFAS
123"), the Company has elected to continue to account for its
stock-based compensation programs according to the provisions of
Accounting Principles Board Opinion No. 25, "Accounting for Stock
Issued to Employees." Accordingly, compensation expense has been
recognized to the extent of employee or director services rendered
based on the intrinsic value of compensatory options or shares granted
under the plans. The Company has adopted the disclosure provisions
required by SFAS 123.
Had the company's stock-based compensation been determined by the
fair-value based method of SFAS 123, "Accounting for Stock-Based
Compensation," the company's net loss and loss per share would have
been as follows:
FOR THE YEAR ENDED
2002 2001 2000
Net loss, as reported $(27,641,519) $(16,174,861) $ (8,720,553)
Add: Stock-based compensation expense included
in reported net loss 141,874 512,707 76,048
Deduct: Total stock-based compensation expense determined
under fair-value based method for all awards (2,591,717) (2,605,307) (1,983,748)
------------ ------------ ------------
Proforma net loss $(30,091,362) $(18,267,461) $(10,628,253)
============ ============ ============
Basic and diluted loss per share:
As reported $ (1.03) $ (0.63) $ (0.40)
Proforma $ (1.12) $ (0.72) $ (0.49)
25
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
Additional disclosures required under SFAS 123 are presented in Note 8.
CONCENTRATION OF CREDIT RISK
From time to time, the Company maintains cash in bank accounts that
exceed the FDIC insured limits. The Company has not experienced any
losses on its cash accounts.
COMPREHENSIVE LOSS
In accordance with Statement of Financial Accounting Standards ("SFAS")
No. 130, "Reporting Comprehensive Income" ("SFAS 130"), which requires
the presentation of the components of comprehensive loss in the
Company's financial statements. Comprehensive loss is defined as the
change in the Company's equity during a financial reporting period from
transactions and other circumstances from non-owner sources (including
cumulative translation adjustments and unrealized gains/losses on
available for sale securities). Accumulated other comprehensive (loss)
income included in the Company's balance sheet is comprised of
translation adjustments from the Company's foreign subsidiaries and
unrealized gains and losses on investment in marketable securities.
RECENT ACCOUNTING PRONOUNCEMENTS
In July 2001, SFAS No. 141, "Business Combinations" ("SFAS 141") and
SFAS No. 142, "Goodwill and Other Intangible Assets" ("SFAS 142") were
issued. SFAS 141 establishes accounting and reporting for business
combinations by requiring that all business combinations be accounted
for under the purchase method. Use of the pooling-of-interests method
is no longer permitted. Statement 141 requires that the purchase method
be used for business combinations initiated after June 30, 2001. The
adoption of SFAS 141 did not have a material impact on the Company's
financial condition or results of operations. SFAS 142 requires that
goodwill no longer be amortized to earnings, but instead be reviewed
for impairment. The Company adopted the Statement effective January 1,
2002. The adoption of SFAS 142 did not have a material impact on the
Company's financial condition or results of operations.
In August 2001, SFAS No. 144 "Accounting for the Impairment or Disposal
of Long-Lived Assets," was issued, replacing SFAS No. 121, "Accounting
for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be
Disposed Of," and portions of APB Opinion 30, "Reporting the Results of
Operations." SFAS No. 144 provides a single accounting model for
long-lived assets to be disposed of and changes the criteria that would
have to be met to classify an asset as held-for-sale. SFAS No. 144
retains the requirement of APB Opinion 30 to report discontinued
operations separately from continuing operations and extends that
reporting to a component of an entity that either has been disposed of
or is classified as held for sale. SFAS No. 144 is effective January 1,
2002 for the Company. The adoption of SFAS 144 did not have a material
impact on the Company's financial condition or results of operations.
In July 2002, the SFAS No. 146 ("SFAS 146") "Accounting for Costs
Associated with Exit or Disposal Activities." SFAS 146 requires
companies to recognize costs associated with exit or disposal
activities when they are incurred rather than at the date of a
commitment to an exit or disposal plan as was the case in prior
guidance by EITF Issue No. 94-3, "Liability Recognition for Certain
Employee Termination Benefits and Other Costs to Exit an Activity
(including Certain Costs Incurred in a Restructuring)." SFAS 146
replaces EITF Issue No. 94-3. SFAS 146 is effective for exit or
disposal activities initiated after December 31, 2002. The Company will
adopt the provisions of SFAS 146 as of January 1, 2003.
26
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
In December 2002, the SFAS No. 148 ("SFAS 148"), Accounting for
Stock-Based Compensation-Transition and Disclosure. SFAS 148 amends
SFAS No. 123, Accounting for Stock-Based Compensation, to provide
alternative methods of transition for a voluntary change to the fair
value based method of accounting for stock-based employee compensation.
In addition, SFAS 148 amends the disclosure requirements of SFAS 123 to
require prominent disclosures in both annual and interim financial
statements about the method of accounting for stock based employee
compensation and the effect of the method used on reported results. The
provisions of SFAS 148 are effective for financial statements for
fiscal years and interim periods ending after December 15, 2002. The
disclosure provisions of SFAS 148 have been adopted by the Company (see
Note 1 of the Notes to Consolidated Financial Statements). SFAS 148 did
not require the Company to change to the fair value based method of
accounting for stock-based compensation.
In November 2002, Interpretation No. 45, "Guarantor's Accounting and
Disclosure Requirements for Guarantees, Including Indirect Guarantees
of Indebtedness of Others" ("FIN 45") was issued. FIN 45 requires at
the time a company issues a guarantee, the company must recognize an
initial liability for the fair market value of the obligations it
assumes under that guarantee and must disclose that information in its
interim and annual financial statements. The initial recognition and
measurement provisions are effective on a prospective basis to
guarantees issued or modified after December 31, 2002. The adoption of
this Interpretation is not expected to have a material effect on the
Company's consolidated financial statements.
In January 2003, Interpretation No. 46 "Consolidation of Variable
Interest Entities" (FIN 46) was issued. Variable Interest Entities
("VIEs") are entities where control is achieved through means other
than voting rights. FIN 46 provides guidance on the identification of
and financial reporting for VIEs. A VIE is required to be consolidated
if the company is subject to the majority of the risk of loss from the
VIE's activities or is entitled to receive a majority of the entity's
residual returns, or both. The consolidation requirements for VIEs
created after January 31, 2003 are effective immediately and
consolidation requirements apply to existing entities in the first
fiscal year or interim period beginning after June 15, 2003. The
adoption of this Interpretation is not expected to have a material
effect on the company's consolidated financial statements.
ACCOUNTING ESTIMATES
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates
that affect the reported amounts of assets and liabilities at the date
of the financial statements and the reported amounts of revenues and
expenses during the reporting period. The Company's most significant
estimates relate to the valuation of its long-lived assets and
estimated cost to complete under its research contracts. Actual results
may differ from those estimates.
3. NOTES RECEIVABLE
The Company has advanced its Asian licensee funds to finance the
purchase of certain equipment. In February 2002, the Company received a
note, in the original principal amount of $309,575, to evidence these
advances. The note bears interest at 6% per annum and is payable in
monthly installments of principal and interest through February 2004.
27
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
4. FIXED ASSETS
Fixed assets at December 31, 2002 and 2001 are comprised of the
following:
2002 2001
Land 363,909 --
Building 7,116,929 2,264,964
Machinery and equipment 1,761,926 1,319,568
Capital lease - Equipment 2,224,886 1,113,459
Computer software 565,158 596,900
Furniture and fixtures 343,971 238,888
Leasehold improvements 634,624 3,048,625
------------ ------------
13,011,403 8,582,404
Less: accumulated depreciation (1,503,839) (890,887)
------------ ------------
$ 11,507,564 $ 7,691,517
------------ ------------
Depreciation and amortization expense was $882,855, $527,011, and
$257,149 for 2002, 2001 and 2000 respectively, of which $268,716,
$74,230 and $0 related to capital leases for the respective years.
Accumulated amortization of assets under capital leases was $371,366
and $74,230 at December 31, 2002 and 2001 respectively.
5. NOTES PAYABLE
On June 11, 2002, the Company issued a convertible note (the "Note")
with a face value of $5 million to two purchasers. The Note is payable
on November 30, 2005 and is collateralized by the Company's
manufacturing facility in East Windsor, New Jersey. The Note is
initially convertible into shares of the Company's common stock at a
conversion price initially equal to $4.08 per share (1,225,490 shares).
If the Company were to issue shares of its common stock at per share
prices lower than the conversion price of the Note, the conversion
price may be adjusted lower. Interest accretes on the Note on a
semi-annual basis at a rate of 5% per annum, and the Company may pay
such amounts in cash or by effecting the automatic conversion of such
amount into the Company's common stock at a 10% discount to the then
average market prices. Subject to certain exceptions, the Company has
prepayment rights for portions of the principal amount, payable in cash
or by conversion into common stock at a 10% discount to average market
prices. The purchasers also received warrants to purchase 389,408
shares of common stock (the "Warrants") at an exercise price equal to
the conversion price of the Note and a term of five years from the date
of issuance. The Company has valued the warrants using the
Black-Scholes pricing model and allocated $795,701 of the proceeds from
the Note, based upon the relative fair value of the Note and the
Warrants, to the Warrants and has recorded such amount as discount on
the Note. The discount is being amortized to interest expense over the
term of the Note. Assumptions utilized in the Black-Scholes model to
value the Warrants were: exercise price of $4.08 per share; fair value
of the Company's common stock on date of issuance of $3.00 per share;
volatility of 100%; term of five years and a risk-free interest rate of
3%. In February 2003, the warrants were subsequently exercised and the
conversion price reduced (Note 15).
28
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
In the event the Company were to issue common stock at per share prices
less than $4.08 (now $2.75 - see Note 15) resulting in the conversion
price of the Note to be adjusted lower, or if the Company were to repay
all or a portion of the interest or Note in common stock, the Company
may be required to record charges to operations in future periods and
the charge could be material.
In addition, the Company paid a placement agent $125,000 in cash and
issued to the placement agent warrants to acquire 38,941 shares of the
Company's common stock at an exercise price of $4.01 per share and a
term of three years from the date of issuance. The Company valued the
placement agent's warrants at $66,861 using the Black-Scholes pricing
model with the following assumptions: exercise price of $4.01 per
share; fair value of the Company's common stock on date of issuance of
$3.00 per share; volatility of 100%; term of three years and a
risk-free interest rate of 2.7%. The Company has recorded the $125,000
cash payment and the fair value of the warrants issued to the placement
agent as a debt issuance cost, which is being amortized to interest
expense over the term of the Note. In addition, professional fees
totaling $163,602 associated with the closing of the Note were also
recorded as debt issuance cost and are being amortized over the term of
the Note.
For the year ended December 31, 2002, the Company recorded amortization
of $126,006 and $57,575 of the debt discount and closing costs
respectively.
6. LINE OF CREDIT
In February 2001, the Company entered into a financial arrangement with
GE Capital Corporation for a line of credit, which provided for the
financing of up to $5 million of equipment (i) for its new East
Windsor, NJ manufacturing facility and (ii) for its expanded corporate
and laboratory facilities in Robbinsville, NJ. Equipment financed
through this facility has been in the form of a 42 month capital lease.
As of December 31, 2002, the Company had financed $1,113,459 of
equipment purchases under the GE credit line. The $5 million credit
line expired in March 2002, and as of December 31, 2002, there was an
outstanding balance due GE of $724,577 under this facility. This
balance is payable in monthly installments through various dates in
2004.
In January 2002, GE approved a new credit line, which provides for the
financing of up to $3 million of equipment and expired on December 31,
2002. During 2002, the Company accessed $1,111,427 of the credit line.
As of December 31, 2002, there was an outstanding balance due GE of
$987,310 under January 2002 facility. Balances due are payable in 42
monthly installments from date of take-down. As of December 31, 2002,
the facility is no longer available to the Company.
7. RELATED PARTY TRANSACTIONS
In July 2001, the Company advanced $100,000 to Vivian Liu, the
Company's Vice President and Secretary. The advance was evidenced by a
promissory note, which bore interest at 5% per annum and was due on May
24, 2002. Prior to the due date, the principal amount due was rolled
into a new promissory note, which bore interest at 5% per annum and had
a new due date of December 31, 2002. As of September 30, 2002, the
principal amount of $100,000 was repaid along with all interest due.
In April 2002, the Company advanced $150,000 to James L. Yeager, Ph.D.,
the Company's Senior Vice President for Scientific Affairs and a
director. The amount of $115,725 remained outstanding as of December
31, 2002. The advance is evidenced by a promissory note, which bears
interest at 5% per annum and was due on November 15, 2002. The note was
not paid in full by November 15,
29
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
2002 and is currently in default. According to the terms of the note,
upon default the interest rate increased to 15% per annum. Interest due
on the promissory note at the default rate of 15% has been paid on a
timely basis. The note receivable is included in the Condensed
Consolidated Balance Sheet under "Prepaid Expenses and Other Assets".
8. STOCK OPTIONS
During October 1996 the Company adopted a Non-Qualified Stock Option
Plan ("Stock Option Plan") and reserved 100,000 shares of common stock
for issuance pursuant to the Plan. During December 1996, the Company
also adopted The NexMed, Inc. Stock Option and Long-Term Incentive
Compensation Plan ("the Incentive Plan") and The NexMed, Inc.
Recognition and Retention Stock Incentive Plan ("the Recognition
Plan"). A total of 2,000,000 shares were set aside for these two plans.
In May 2000, the Stockholders' approved an increase in the number of
shares reserved for the Incentive Plan and Recognition Plan to a total
of 7,500,000. Options granted under the Company's plans generally vest
over a period of one to five years, with exercise prices ranging
between $0.50 to $16.50. The maximum term under these plans is 10
years.
30
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
A summary of stock option activity is as follows:
WEIGHTED
AVERAGE
NUMBER OF EXERCISE
SHARES PRICE
Outstanding at December 31, 1999 2,457,700 1.66
Granted 1,962,225 5.43
Exercised (686,500) 0.85
Cancelled (150,750) 7.23
--------- --------
Outstanding at December 31, 2000 3,582,675 3.67
--------- --------
Granted 537,400 0.75
Exercised (189,550) 2.02
Cancelled (95,950) 6.77
--------- --------
Outstanding at December 31, 2001 3,834,575 $ 3.72
--------- --------
Granted 1,555,573 1.35
Exercised (53,000) 0.35
Cancelled (586,393) 4.04
--------- --------
Outstanding at December 31, 2002 4,750,755 $ 2.92
--------- --------
Exercisable at December 31, 2002 3,162,900 $ 3.46
--------- --------
Exercisable at December 31, 2001 2,731,291 $ 3.26
--------- --------
Exercisable at December 31, 2000 2,244,433 $ 2.59
--------- --------
Options available for grant at December 31, 2002 2,430,195
---------
The following table summarizes information about options outstanding at
December 31, 2002:
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
---------------------------------------------------- --------------------------------
WEIGHTED AVERAGE
RANGE OF NUMBER REMAINING WEIGHTED AVERAGE NUMBER WEIGHTED AVERAGE
EXERCISE PRICES OUTSTANDING CONTRACTUAL LIFE EXERCISE PRICE EXERCISABLE EXERCISE PRICE
$ .50 - 1.75 1,088,555 9.05 years $ 0.71 91,500 $ 1.51
2.00 - 3.50 2,029,600 5.83 years 2.38 1,521,200 2.17
4.00 - 5.50 1,442,200 7.13 years 4.05 1,401,600 4.03
7.00 - 8.00 65,000 3.44 years 7.46 55,000 7.36
12.00 - 16.25 125,400 7.82 years 15.59 93,600 15.66
--------- ------ --------- ------
4,750,755 $ 2.92 3,162,900 $ 3.46
--------- ------ --------- ------
The weighted average grant date fair value of options granted during
2002, 2001 and 2000 was $1.23, $2.26 and $3.62, respectively.
31
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
The fair value of each option and warrant (note 11) is estimated on the
date of grant using the Black-Scholes option-pricing model. The following
assumptions were used in the model:
2002 2001 2000
Dividend yield 0.00% 0.00% 0.00%
Risk-free yields 1.35% - 3.00% 4.39% - 6.71% 4.39% - 6.71%
Expected volatility 100% 65% - 80% 65% - 80%
Option terms 1 - 10 years 1 - 10 years 1 - 10 years
9. COMMON STOCK
On June 28, 2002, the Company completed a private placement of its
securities to institutional and accredited individual investors. The
Company issued a total of 2,666,670 shares of its common stock and
warrants to purchase 533,334 shares of common stock, pursuant to a Unit
Purchase Agreement. Gross proceeds from the private placement were
$6,000,000. The investors paid $11.25 per unit and received five shares
of NexMed common stock and a two-year warrant for the right to purchase
one share of common stock at $2.81.
In connection with the private placement, the Company paid a placement
agent $249,938 in cash and issued the placement agent warrants to
purchase 222,167 shares of the Company's common stock at an exercise
price of $2.81 per share and a term of three years from the date of
issuance.
In August 2000, the Company completed unit offerings of 3,138,256
shares of its common stock and warrants to acquire 1,282,891 shares of
its common stock to 25 accredited individuals and financial
institutions. The warrants have an exercise price of $13.50 to $16.20
per share and a term of eighteen months. The price of the units ranged
from $16.54 to $18.00, depending on the date of closing and/or amount
of warrant coverage. The Company raised $26,848,139 in gross proceeds
and $24,879,281 in net proceeds, after deducting commissions and
offering expenses, in connection with these offerings. In addition, the
Company issued warrants to acquire an aggregate of 305,426 shares of
its common stock, with exercise prices ranging from $13.65 to $16.20
per share, to the placement agents in the offering.
In June 2000, the Articles of Incorporation were amended to increase
the number of shares of common stock authorized for issuance from
40,000,000 to 80,000,000.
In April 2000, the Company completed a private placement of 220,000
shares of its common stock at $14.25 per share, raising gross proceeds
of $3,135,000 and net proceeds, after deducting commissions and
offering expenses, of $2,946,900.
10. STOCKHOLDER RIGHTS PLAN
On April 3, 2000, the Company declared a dividend distribution of one
preferred share purchase right (the "Right") for each outstanding share
of the Company's common stock to shareholders of record at the close of
business on April 21, 2000. One Right will also be distributed for each
share of Common Stock issued after April 21, 2000, until the
Distribution Date, described in the next paragraph. Each Right entitles
the registered holder to purchase from the Company a unit
32
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
consisting of one one-hundredths of a share (a "Unit") of Series A
Junior Participating Preferred Stock, $.001 par value per share (the
"Preferred Stock"), at a Purchase Price of $100.00 per Unit, subject to
adjustment. 1,000,000 shares of the Company's preferred stock has been
set-aside for the Rights Plan.
Initially, the Rights will be attached to all Common Stock certificates
representing shares then outstanding, and no separate Rights
Certificates will be distributed. The Rights will separate from the
Common Stock and a Distribution Date will occur upon the earlier of (i)
ten (10) business days following a public announcement that a person or
group of affiliated or associated persons (an "Acquiring Person") has
acquired, or obtained the right to acquire, beneficial ownership of 15%
or more of the outstanding shares of Common Stock (the "Stock
Acquisition Date"), or (ii) ten (10) business days following the public
announcement of a tender offer or exchange offer that would, if
consummated, result in a person or group beneficially owning 15% or
more of such outstanding shares of Common Stock, subject to certain
limitations.
Under the terms of the Rights Agreement, Dr. Y. Joseph Mo, who
beneficially owned approximately 12.12% of the outstanding shares of
the Company's Common Stock as of April 2000, will be permitted to
continue to own such shares and to increase such ownership to up to 25%
of the outstanding shares of Common Stock, without becoming an
Acquiring Person and triggering a Distribution Date.
11. WARRANTS
A summary of warrant activity is as follows:
WEIGHTED
COMMON SHARES AVERAGE
ISSUABLE UPON EXERCISE
EXERCISE PRICE
Outstanding at January 1, 2000 5,705,726 2.52
Issued 1,588,317 14.59
Exercised (4,973,494) 2.54
Redeemed (29,000) 2.25
---------- -----
Outstanding at December 31, 2000 2,291,549 10.85
Issued 115,000 12.22
Exercised (200,000) 3.00
---------- -----
Outstanding at December 31, 2001 2,206,549 11.59
---------- -----
Issued 1,183,850 3.27
Redeemed (1,345,491) 14.31
---------- -----
Outstanding at December 31, 2002 2,044,908 5.03
---------- -----
In connection with the private placement on June 28, 2002 (Note 9), the
Company issued warrants to purchase 533,334 shares of common stock ,
pursuant to a Unit Purchase Agreement. The investors paid $11.25 per
unit and received five shares of NexMed common stock and a two-year
warrant for the right to purchase one share of common stock at $2.81.
The Company also issued the placement agent warrants to purchase
222,167 shares of the Company's common stock at an exercise price of
$2.81 per share and a term of three years from the date of issuance.
33
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
In August 2001, the Company issued warrants to acquire 15,000 shares of
its common stock to a financial consultant. The warrants have an
exercise price of $7.00 per share and vested immediately. In accordance
with EITF 96-18, the Company has recorded $38,550 of consulting
expenses related to these warrants, representing the fair value of
these warrants using the Black-Scholes pricing model.
In February 2001, the Company issued warrants to acquire 100,000 shares
of its common stock to a financial consultant. The warrants have an
exercise price of $13.00 per share, of which 34,000 warrants vested
immediately and the remaining warrants vested in two equal installments
on May 20, 2001 and August 20, 2001. The warrants have a three-year
term. In accordance with EITF 96-18, the Company has recorded
approximately $297,500 of consulting expense related to these warrants
during 2001, representing the fair value of these warrants using the
Black-Scholes pricing model.
In August 2000, the Company issued warrants to acquire an aggregate of
1,588,317 shares of its common stock to the investors and placement
agents in a private placement of its securities (see Note 9). The
warrants have exercise prices ranging from $13.50 to $16.20 per share.
1,295,491 warrants expired in February 2002 and 292,826 warrants issued
as commission to a placement agent expire in August 2003.
12. INCOME TAXES
The Company has incurred losses since inception, which have generated
net operating loss carryforwards of approximately $35.4 million for
federal and state income tax purposes. These carryforwards are
available to offset future taxable income and expire beginning in 2011
for federal income tax purposes. In addition, the Company has general
business and research and development tax credit carryforwards of
approximately $3.8 million. Internal Revenue Code Section 382 places a
limitation on the utilization of Federal net operating loss
carryforwards when an ownership change, as defined by tax law, occurs.
Generally, an ownership change, as defined, occurs when a greater than
50 percent change in ownership takes place during any three-year
period. The actual utilization of net operating loss carryforwards
generated prior to such changes in ownership will be limited, in any
one year, to a percentage of fair market value of the Company at the
time of the ownership change. Such a change may have already resulted
from the additional equity financing obtained by the Company since its
formation.
In 2002, the Company was approved by the State of New Jersey to sell a
portion of its state tax credits pursuant to the Technology Tax
Certificate Transfer Program. The Company has approximately $1.65
million in NJ tax credits, and was approved to sell $279,000 in 2002.
The Company received proceeds of $242,645 in 2002 as a result of the
sale of the tax credits.
The net operating loss carryforwards and tax credit carryforwards
result in a noncurrent deferred tax benefit at December 31, 2002 and
2001 of approximately $17.9 million and $8.7 million, respectively. In
consideration of the Company's accumulated losses and the uncertainty
of its ability to utilize this deferred tax benefit in the future, the
Company has recorded a valuation allowance of an equal amount on such
date to fully offset the deferred tax benefit amount.
For the years ended December 31, 2002, 2001 and 2000, the Company's
effective tax rate differs from the federal statutory rate principally
due to net operating losses and other temporary differences for which
no benefit was recorded, state taxes and other permanent differences.
34
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
13. COMMITMENTS AND CONTINGENCIES
The Company is a party to several short-term consulting and research
agreements which, generally, can be cancelled at will by either party.
The Company leases office space and research facilities under operating
lease agreements expiring through 2006. The Company also leases
equipment from GE Capital under capital leases expiring through 2005
(Note 6). Future minimum payments under noncancellable operating and
capital leases with initial or remaining terms of one year or more,
consist of the following at December 31, 2001:
OPERATING CAPITAL
2003 $ 488,114 $ 741,017
2004 132,964 741,017
2005 27,759 432,655
2006 3,150 39,278
2007 2,100 --
---------- ----------
Total minimum lease payments $ 654,087 1,953,967
----------
Less: amount representing interest (242,080)
Present value of future minimum lease payments 1,711,887
Less: current portion (609,676)
----------
Capital lease obligations, net of current portion $1,102,211
----------
The Company also leases office space under short-term lease agreements.
Total rent expense was $452,052, $535,023, and $310,326 in 2002, 2001,
and 2000 respectively.
On February 27, 2002, the Company entered in to an employment agreement
with Y. Joseph Mo, Ph.D., that has a constant term of five years, and
pursuant to which Dr. Mo will serve as the Company's Chief Executive
Officer and President. During his employment with the Company, Dr. Mo
will receive an annual base salary of at least $250,000 (to be raised
to $350,000 after the Company sustains gross revenues of $10 million
for two consecutive fiscal quarters), subject to annual cost of living
increases. Under the employment agreement, Dr. Mo is entitled to
deferred compensation in an annual amount equal to one sixth of the sum
of Dr. Mo's base salary and bonus for the 36 calendar months preceding
the date on which the deferred compensation payments commence subject
to certain limitations, including annual vesting through January 1,
2007, as set forth in the employment agreement. The deferred
compensation will be payable monthly for 180 months commencing on
termination of employment. As of December 31, 2002, the Company has
accrued approximately $350,000, which is included in accounts payable
and accrued expenses, based upon the estimated present value of the
vested portion of the obligation.
35
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
14. SEGMENT AND GEOGRAPHIC INFORMATION
In 1998, the Company adopted SFAS 131, "Disclosures about Segments of
an Enterprise and Related Information". SFAS 131 establishes standards
for reporting information regarding operating segments and related
disclosures about products and services, geographic areas and major
customers.
The Company is active in one business segment: designing, developing,
manufacturing and marketing pharmaceutical products. The Company
maintains development and marketing operations in the United States,
Hong Kong and Canada.
Geographic information as of December 31, 2001, 2000 and 1999 are as
follows:
2002 2001 2000
NET REVENUES
Other foreign countries $ 148,028 $ 68,089 $ --
------------ ------------ ------------
$ 148,028 $ 68,089 $ --
------------ ------------ ------------
NET LOSS
United States $(27,538,701) $(16,106,246) $ (8,630,255)
Other foreign countries (102,818) (68,615) (90,298)
------------ ------------ ------------
$(27,641,519) $(16,174,861) $ (8,720,553)
------------ ------------ ------------
TOTAL ASSETS
United States $ 14,027,334 $ 27,286,173 $ 39,516,217
Other foreign countries 112,793 28,540 473,465
------------ ------------ ------------
$ 14,140,127 $ 27,314,713 $ 39,989,682
------------ ------------ ------------
15. SUBSEQUENT EVENTS
On February 4, 2003 the terms of the convertible notes (Note 5) were
amended. In order to induce the holders to exercise the Warrants in
full, the Company agreed to reduce the conversion price under the notes
to $2.75 and the warrant exercise price was reduced to $1.37
(originally $4.08) per share. Pursuant to the amendment, all of the
warrants were exercised on February 4, 2003 and the Company received
proceeds of $533,489 from such exercise. The Company is in the process
of evaluating this transaction and may be required to record charges
related to the reduction of the conversion price and the warrant
exercise price. These charges may be material.
On January 31, 2003, the Company entered into a 11 month consulting
agreement with a financial consultant (the "Consultant") for investor
relations and financial consulting services. The Company agreed to pay
the consultant a fee of $395,000 and will issue the Consultant
immediately exercisable warrants to purchase 500,000 shares of the
Company's common stock with an exercise price of $1.00 on April 10,
2003. The Company has granted the Consultant registration
36
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
rights for such shares. In accordance with EITF 96-18, the Company will
record consulting expenses based on the fair value of these warrants on
April 10, 2003, calculated using the Black-Scholes pricing model. The
Company also agreed to pay the consultant 10% of any funding as a
result of an introduction made by the Consultant, and 8% of the total
aggregate consideration paid for any acquisition or sale by the Company
of any businesses.
On January 17, 2003 and February 1, 2003, the Company issued two
one-month notes of $500,000 and $100,000 respectively. The notes bore
interest at 12% per annum and were convertible into securities at such
time as the Company closes a private placement of its securities. The
conversion rate was the purchase price of the securities in the
private placement. If the notes were not repaid on the maturity date,
the noteholder had the option of extending the maturity of the notes
for an additional one month at an interest rate of 15%. The notes were
not repaid on the maturity date, and both were extended to March 21,
2003. On March 21, 2003, the Company closed a private placement of its
common stock at $1.50 per share. The note-holder elected to convert the
outstanding $614,064 in principal and interest due into 409,376 shares
of the Company's common stock and 307,032 three-year warrants to
purchase the Company's common stock at $2.00 per share.
As mentioned in the preceding paragraph, on March 21, 2003, the Company
closed a private placement of its common stock at $1.50 per share.
Pursuant to the agreement of the private placement, the Company issued
a total of 209,987 shares and 157,490 three-year warrants to purchase
the Company's common stock at $2.00 per share to three accredited
investors and received $314,980 in gross proceeds. As a result of the
March 21 issuances of common stock, the conversion price of the
convertible notes was reduced to $2.72.
In March 2003, the Company issued one short-term promissory note due
May 4, 2003 for $500,000 to one accredited investor. This promissory
note bears interest at 15% per annum and provides for two-year
warrants to purchase 50,000 shares of the Company's common stock, at
an exercise price of $2.00 per share. The Company has valued the
warrants using the Black-Scholes pricing model and allocated $42,000
of the proceeds from the note, based upon the relative fair value of
the note and the warrants, to the warrants and has recorded such
amount as discount on the note.
37
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None.
PART III.
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.
Information called for by Item 10 is set forth under the heading
"Election of Directors" in the 2003 Proxy Statement, which is incorporated
herein by this reference and "Executive Officers" of Part I of this Report.
ITEM 11. EXECUTIVE COMPENSATION.
Information called for by Item 11 is set forth under the heading
"Executive Compensation" in the 2003 Proxy Statement, which is incorporated
herein by this reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS.
Information called for by Item 12 is in part set forth under the heading
"Security Ownership of Certain Beneficial Owners and Management" in the 2003
Proxy Statement, which is incorporated herein by this reference, and in part set
forth below.
EQUITY COMPENSATION PLAN INFORMATION
The following table gives information as of December 31, 2002, about
NexMed Stock that may be issued upon the exercise of options, warrants and
rights under all of our existing equity compensation plans (together, the
"Equity Plans").
EQUITY COMPENSATION PLAN INFORMATION
----------------------------------------------------------------------------------------------------
(A) NUMBER OF SECURITIES REMAINING
NUMBER OF SECURITIES TO BE (B) AVAILABLE FOR FUTURE ISSUANCE
ISSUED UPON EXERCISE OF WEIGHTED AVERAGE EXERCISE PRICE UNDER EQUITY COMPENSATION
OUTSTANDING OPTIONS, WARRANTS OF OUTSTANDING OPTIONS, WARRANTS PLANS (EXCLUDING SECURITIES
PLAN CATEGORY AND RIGHTS AND RIGHTS REFLECTED IN COLUMN (A))
- ------------------ ----------------------------- -------------------------------- ---------------------------
Equity Plans
approved by
security holders 4,750,755(1) $2.92 2,370,195(2)
Equity Plans not
approved by
security holders -- N/A --
------------ ----- ------------
Total 4,750,755(1) $2.92 2,370,195(2)
------------ ----- ------------
(1) Consists of options outstanding at December 31, 2002 under The NexMed Inc.
Stock Option and Long Term Incentive Plan (the "Incentive Plan") and The
NexMed Inc. Recognition and Retention Stock Incentive Plan (the
"Recognition Plan").
(2) Consists of the aggregate number of shares of Stock that remain available
for future issuance, at December 31, 2002, under all of our stockholder
approved Equity Plans. This consists of 1,637,795 shares available under
the Incentive Plan and 732,400 shares available under the Recognition
Plan.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
Information called for by Item 13 is set forth under the heading "Certain
Relationships and Related Transactions" in the 2003 Proxy Statement, which is
incorporated herein by this reference.
ITEM 14. CONTROLS AND PROCEDURES.
Within the 90 days prior to the date of filing of this report, we carried
out an evaluation, under the supervision and participation of our management
(including our Chief Executive Officer and Acting Chief Financial Officer, our
principal executive officer and principal financial officer, respectively), of
the effectiveness and design and operation of the Company's controls and
procedures pursuant to Exchange Act Rule 13a-15. Based upon that evaluation, our
Chief Executive Officer and Acting Chief Financial Officer concluded that our
disclosure controls and procedures are effective in timely alerting them to
information required to be included in our periodic Securities and Exchange
Commission filings. There were no significant changes in our internal controls
or in other factors that could significantly affect these controls subsequent to
the date of their evaluation.
PART IV.
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K.
(A) 1. FINANCIAL STATEMENTS:
The information required by this item is included in Item 8 of Part II
of this Form 10-K.
2. FINANCIAL STATEMENT SCHEDULES
Report of Independent Accountants on Financial Statement Schedule for
the three years in the period ended December 31, 2002.
38
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS.
REPORT OF INDEPENDENT ACCOUNTANTS ON FINANCIAL STATEMENT SCHEDULE
To the Board of Directors and Stockholders of NexMed, Inc.
Our audits of the consolidated financial statements referred to in our report
dated February 25, 2003, except as to Note 15 which is as of March 21, 2003,
which included an explanatory paragraph regarding the Company's ability to
continue as a going concern, appearing in this Annual Report on Form 10-K also
included an audit of the financial statement schedules listed in Item 15(a)(2)
of this Form 10-K. In our opinion, these financial statement schedules present
fairly, in all material respects, the information set forth therein when read in
conjunction with the related consolidated financial statements.
/s/ PricewaterhouseCoopers LLP
- ------------------------------
PricewaterhouseCoopers LLP
New York, New York
February 25, 2003
SCHEDULE II
NEXMED, INC.
SCHEDULE OF VALUATION AND QUALIFYING ACCOUNTS
Balance at Charged to Charged to
Beginning Costs and Other Balance at
Description of Year Expenses Accounts Deductions End of Year
----------- ------- -------- -------- ---------- -----------
YEAR ENDED DECEMBER 31, 2002
Valuation allowance - deferred tax asset $8,699,708 $9,201,826 -- -- $17,901,534
YEAR ENDED DECEMBER 31, 2001
Valuation allowance - deferred tax asset $4,572,023 $4,127,685 -- -- $ 8,699,708
YEAR ENDED DECEMBER 31, 2000
Valuation allowance - deferred tax asset $2,491,607 $2,080,416 -- -- $ 4,572,023
--
All other schedules have been omitted because the information is not applicable
or is presented in the Financial Statements or Notes thereto.
3. EXHIBITS
EXHIBITS DESCRIPTION
NO.
- ---
3.1 Amended and Restated Articles of Incorporation of the Company
(incorporated by reference to Exhibit 2.1 filed with the
Company's Form 10-SB filed with the Securities and Exchange
Commission on March 14, 1997).
3.2 Certificate of Amendment to Articles of Incorporation of the
Company, dated June 22, 2000.
3.3 By-laws of the Company (incorporated by reference to Exhibit
2.2 filed with the Company's Form 10-SB filed with the
Securities and Exchange Commission on March 14, 1997).
3.4 Amendment to By-laws of the Company (incorporated by reference
to Exhibit 2.3 filed with the Company's Form 10-SB filed with
the Securities and Exchange Commission on March 14, 1997).
39
4.1 Form of Common Stock Certificate (incorporated by reference to
Exhibit 3.1 filed with the Company's Form 10-SB filed with the
Securities and Exchange Commission on March 14, 1997).
4.2 Rights Agreement and form of Rights Certificate (incorporated
herein by reference to Exhibit 4 to our Current Report on Form
8-K filed with the Commission on April 10, 2000).
4.3 Certificate of Designation of Series A Junior Participating
Preferred Stock (incorporated herein by reference to Exhibit 4
to our Current Report on Form 8-K filed with the Commission on
April 10, 2000).
4.4 Form of 5% Convertible Note dated June 11, 2002 (incorporated
herein by reference to Exhibit 4.2 to the Company's S-3 filed
with the Securities and Exchange Commission on July 19, 2002).
4.5 Form of Warrant dated June 11, 2002 (incorporated herein by
reference to Exhibit 4.3 to the Company's S-3 filed with the
Securities and Exchange Commission on July 19, 2002).
4.6 Form of Unit Warrant dated June 28, 2002 (incorporated herein
by reference to Exhibit 4.5 to the Company's S-3 filed with the
Securities and Exchange Commission on July 19, 2002).
4.7 Form of Placement Agent Warrant dated June 28, 2002
(incorporated herein by reference to Exhibit 4.6 to the
Company's S-3 filed with the Securities and Exchange Commission
on July 19, 2002).
10.1* Amended and Restated NexMed, Inc. Stock Option and Long-Term
Incentive Compensation Plan (incorporated by reference to
Exhibit 10.1 filed with the Company's Form 10-Q filed with the
Securities and Exchange Commission on May 15, 2001).
10.2* The NexMed, Inc. Recognition and Retention Stock Incentive Plan
(incorporated by reference to Exhibit 6.5 filed with the
Company's Form 10-SB/A filed with the Securities and Exchange
Commission on June 5, 1997).
10.3 License Agreement dated March 22, 1999 between NexMed
International Limited and Vergemont International Limited
(incorporated by reference to Exhibit 10.7 of the Company's
Form 10-KSB filed with the Securities and Exchange Commission
on March 16, 2000).
10.4 Form of Unit Purchase Agreement between the Company and each
investor who purchased units relating the Company's private
placement dated August and July 2000 (incorporated by reference
to Exhibit 4.2 filed with the Company's Form S-3 filed with the
Securities and Exchange Commission on September 29, 2000).
10.5* Employment Agreement dated February 26, 2002 by and between
NexMed, Inc. and Dr. Y. Joseph Mo. (Incorporated by reference
to Exhibit 10.7 of the Company's Form 10-K filed with the
Securities and Exchange Commission on March 29, 2002.)
10.6 Letter Agreement dated February 6, 2001, by and among NexMed,
Inc. and General Electric Capital Corporation (Incorporated by
reference to Exhibit 10.8 of the Company's Form 10-K filed with
the Securities and Exchange Commission on March 29, 2002.)
10.7 Letter Agreement dated January 2, 2002, by and among NexMed,
Inc. and General Electric Capital Corporation (Incorporated by
reference to Exhibit 10.8 of the Company's Form 10-K filed with
the Securities and Exchange Commission on March 29, 2002.)
10.8 Purchase Agreement between the Company and The Tailwind Fund
Ltd. and Solomon Strategic Holdings, Inc. dated June 11, 2002
(incorporated herein by reference to Exhibit 10.1 to the
Company's Form 10-Q filed with the Securities and Exchange
Commission on August 14, 2002).
40
10.9 Registration Rights Agreement between the Company and The
Tailwind Fund Ltd. and Solomon Strategic Holdings, Inc. dated
June 11, 2002 (incorporated herein by reference to Exhibit 10.1
to the Company's Form 10-Q filed with the Securities and
Exchange Commission on August 14, 2002).
10.10 Subsidiary Guaranty by NexMed (U.S.A.), Inc., a wholly owned
subsidiary of the Company, in favor of The Tailwind Fund Ltd.
and Solomon Strategic Holdings, Inc. dated June 11, 2002
(incorporated herein by reference to Exhibit 10.1 to the
Company's Form 10-Q filed with the Securities and Exchange
Commission on August 14, 2002).
10.11 Mortgage, Security Agreement and Assignment of Leases and Rents
by NexMed (U.S.A.), Inc., a wholly owned subsidiary of the
Company, in favor of The Tailwind Fund Ltd. and Solomon
Strategic Holdings, Inc. dated June 11, 2002 (incorporated
herein by reference to Exhibit 10.1 to the Company's Form 10-Q
filed with the Securities and Exchange Commission on August 14,
2002).
10.12 Form of Unit Purchase Agreement dated June 28, 2002
(incorporated herein by reference to Exhibit 10.1 to the
Company's Form 10-Q filed with the Securities and Exchange
Commission on August 14, 2002).
21 List of Subsidiaries.
23 Consent of PricewaterhouseCoopers LLP, independent accountants.
99.1 Certification of Chief Executive Officer pursuant to Section
906 of the Sarbanes-Oxley Act of 2002.
99.2 Certification of Acting Chief Financial Officer pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
*Management compensatory plan or arrangement required to be filed as an exhibit
pursuant to Item 15(c) of Form 10-K.
(B) REPORTS ON FORM 8-K
None.
41
SIGNATURES
Pursuant to the requirements of the Section 13 or 15(d) of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.
NEXMED, INC.
Dated: March 31, 2003 By: /s/ Y. Joseph Mo
---------------------------------------------
Y. Joseph Mo
Chairman of the Board of Directors, President
and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
SIGNATURE TITLE DATE
/s/ Y. Joseph Mo Chairman of the Board of Directors, President and March 31, 2003
- ---------------- Chief Executive Officer
Y. JOSEPH MO
/s/ Vivian H. Liu Vice President, Acting Chief Financial Officer and March 31, 2003
- ----------------- Secretary
VIVIAN H. LIU
/s/ James Yeager Director, Senior Vice-President, Scientific Affairs March 31, 2003
- ----------------
JAMES YEAGER
/s/ Richard J. Berman Director March 31, 2003
- ---------------------
RICHARD J. BERMAN
/s/ Robert W.Gracy Director March 31, 2003
- -------------------
ROBERT W. GRACY
/s/ Stephen M. Sammut Director March 31, 2003
- ---------------------
STEPHEN M. SAMMUT
42
CERTIFICATION
I, Y. Joseph Mo, Chief Executive Officer of NexMed, Inc., certify that:
1. I have reviewed this annual report on Form 10-K of NexMed, Inc.;
2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;
3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;
4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this annual y report is being prepared;
b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this annual
report (the "Evaluation Date"); and
c) presented in this annual report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent functions:
a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and
b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal controls
or in other factors that could significantly affect internal controls subsequent
to the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.
Date: March 31, 2003
/s/ Y. Joseph Mo
-----------------------
Y. Joseph Mo
Chief Executive Officer
CERTIFICATION
I, Vivian H. Liu, Chief Financial Officer of NexMed, Inc., certify that:
1. I have reviewed this annual report on Form 10-K of NexMed, Inc.;
2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;
3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;
4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this annual y report is being prepared;
b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this annual
report (the "Evaluation Date"); and
c) presented in this annual report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent functions:
a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and
b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal controls
or in other factors that could significantly affect internal controls subsequent
to the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.
Date: March 31, 2003
/s/ Vivian Liu
------------------------------
Vivian H. Liu
Acting Chief Financial Officer
EXHIBIT INDEX
EXHIBITS DESCRIPTION
NO.
3.2 Certificate of Amendment to Articles of Incorporation of the
Company, dated June 22, 2000.
21 List of Subsidiaries.
23 Consent of PricewaterhouseCoopers LLP, independent accountants.
99.1 Certification of Chief Executive Officer pursuant to Section
906 of the Sarbanes-Oxley Act of 2002.
99.2 Certification of Acting Chief Financial Officer pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.